Document:

Exhibit 10.8

 

SUBSCRIPTION AGREEMENT

 

DPCM Capital, Inc.

382 NE 191 Street, #24148

Miami, FL 33179

DPCM Capital, Inc.

 

Ladies and Gentlemen:

 

In connection with the proposed
business combination (the “Transaction”) among DPCM Capital, Inc., a Delaware corporation (the “Company”),
Jam City, Inc., a Delaware corporation (“Old Jam City”), and New Jam City, LLC, a Delaware limited liability company
(“New Jam City”, and, collectively with Old Jam City, “Jam City”), the undersigned (the “Subscriber”)
desires to subscribe for and purchase from the Company, and the Company desires to sell and issue to the Subscriber, that number of shares
of the Company’s Class A Common Stock, par value $0.0001 per share (referred to herein as the “Class A Common Stock”
or “Common Stock”), set forth on the signature page hereof for a purchase price of $8.42 per share (the “Per
Share Price” and the aggregate of such Per Share Price for all Shares (as defined below) subscribed for by the Subscriber being
referred to herein as the “Purchase Price”), on the terms and subject to the conditions contained in this agreement
(this “Subscription Agreement”). In connection with the Transaction, (i) certain other “accredited investors”
(as defined in Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”)) or “qualified
institutional buyers” (as defined in Rule 144A under the Securities Act) have entered into separate subscription agreements with
the Company in substantially the same form as this Agreement, and (ii) certain other “accredited investors” (as defined in
Rule 501 under the Securities Act) have entered into separate subscription agreements with the Company pursuant to separate and concurrent
private placements that are on substantially similar terms and conditions as this Agreement, pursuant to which such other investors have,
together with the Subscriber pursuant to this Subscription Agreement, agreed to purchase an aggregate of 11,876,485 shares of Common Stock
at the Per Share Price (the subscription agreements referred to in the foregoing (i) and (ii) are referred to herein collectively as the
“Other Subscription Agreements” and the investors party to the Other Subscription Agreements are referred to herein
collectively as the “Other Subscribers”). In connection therewith, the Subscriber and the Company agree as follows:

 

1. Subscription.
Subject to the provisions of Section 2 hereof, (i) the Subscriber hereby irrevocably subscribes for and agrees to purchase from the Company
such number of shares of Common Stock as is set forth on the signature page of this Subscription Agreement (the “Shares”)
on the terms and subject to the conditions provided for herein and (ii) the Company hereby irrevocably agrees to issue and sell to the
Subscriber such number of Shares as is set forth on the signature page of this Subscription Agreement on the terms and subject to the
conditions provided for herein.

 

For the purposes of this Subscription
Agreement, “business day” means any other day than a Saturday, Sunday or a day on which the Federal Reserve Bank of
New York is closed.

 

     

    

    

 

2. Closing.
The closing of the sale of the Shares contemplated hereby (the “Subscription Closing”) is contingent upon the substantially
concurrent consummation of the Transaction (the “Transaction Closing”). The Subscription Closing shall occur on the
date of, and immediately prior to, the Transaction Closing (the “Transaction Closing Date”). Not less than five business
days prior to the scheduled or anticipated Transaction Closing Date, the Company shall provide written notice to the Subscriber (the “Closing
Notice”) (i) setting forth the scheduled or anticipated Transaction Closing Date, (ii) stating that the Company reasonably expects
all conditions to the Transaction Closing to be satisfied or waived, and (iii) including wire instructions for delivery of the Purchase
Price to the Escrow Agent (as defined below). The Subscriber shall deliver to Continental Stock Transfer & Trust Company, as escrow
agent (the “Escrow Agent”), at least one business day prior to the Transaction Closing Date specified in the Closing
Notice, the Purchase Price, which shall be held in a segregated escrow account for the benefit of the Subscriber (the “Escrow
Account”) until the Subscription Closing pursuant to the terms of a customary escrow agreement, which shall be on terms and
conditions reasonably satisfactory to the Subscriber to be entered into by the Company and the Escrow Agent (the “Escrow Agreement”),
by wire transfer of United States dollars in immediately available funds to the account specified by the Company in the Closing Notice.
The Company shall provide to the Subscriber, no later than the date on which the Closing Notice is delivered to the Subscriber, a copy
of the executed Escrow Agreement to be in force on the Transaction Closing Date. On the Transaction Closing Date, the Company shall deliver
to the Subscriber (i) the Shares in book-entry form, or, if required by the Subscriber, certificated form, free and clear of any liens
or other restrictions whatsoever (other than those arising under state or federal securities laws as set forth herein), in the name of
the Subscriber (or its nominee in accordance with its delivery instructions) or to a custodian designated by the Subscriber, as applicable,
and (ii) a copy of the records of the Company’s transfer agent showing the Subscriber (or such nominee or custodian) as the
owner of the Shares on and as of the Transaction Closing Date. Upon delivery of the Shares to the Subscriber (or its nominee or custodian,
if applicable), the Purchase Price shall be released from the Escrow Account automatically and without further action by the Company or
the Subscriber.

 

If the Transaction Closing
does not occur within one business day after the Transaction Closing Date specified in the Closing Notice, the Escrow Agent shall promptly
(but not later than one business day thereafter) return the Purchase Price to the Subscriber by wire transfer of U.S. dollars in immediately
available funds to the account specified by the Subscriber. Furthermore, if the Transaction Closing does not occur on the same day as
the Subscription Closing, the Escrow Agent (or the Company, if the Purchase Price has been released by the Escrow Agent) shall promptly
(but not later than one business day thereafter) return the Purchase Price to the Subscriber by wire transfer of U.S. dollars in immediately
available funds to the account specified by the Subscriber, and any book-entries and, if applicable, certificated shares, shall be deemed
cancelled (and, in the case of certificated shares, the Subscriber shall promptly return such certificates to the Company or, as directed
by the Company, to the Company’s representative or agent).

 

If this Subscription Agreement
terminates in accordance with Section 9 hereof following the delivery by the Subscriber of the Purchase Price for the Shares, the Escrow
Agent shall promptly (but not later than one business day after such termination) return the Purchase Price to the Subscriber by wire
transfer of U.S. dollars in immediately available funds to the account specified by the Subscriber.

 

    2

    

    

 

3. Closing
Conditions.

 

a. The
obligations of the Company to consummate the transactions contemplated hereunder are subject to the conditions that, at the Subscription
Closing:

 

		i.	all representations and warranties of the Subscriber contained in this Subscription Agreement shall be
true and correct in all material respects (other than representations and warranties that are qualified as to materiality, which representations
and warranties shall be true and correct in all respects) at and as of the Subscription Closing as though made on the date of the Subscription
Closing (except for those representations and warranties that speak as of a specific date, which shall be so true and correct in all material
respects as of such specified date), but in each case without giving effect to the Transaction Closing (collectively, the “Subscriber
Bring-Down Condition”), and the Subscriber agrees that consummation of the Subscription Closing shall constitute a certification
by the Subscriber to the Company that the Subscriber Bring-Down Condition has been satisfied; and

 

		ii.	the Subscriber shall have performed or complied in all material respects with all agreements and covenants
required by this Subscription Agreement.

 

b. The
obligations of the Subscriber to consummate the transactions contemplated hereunder are subject to the conditions that, at the Subscription
Closing:

 

		i.	all representations and warranties of the Company contained in this Subscription Agreement shall be true
and correct in all material respects (other than representations and warranties that are qualified as to materiality or Material Adverse
Effect (as defined herein), which representations and warranties shall be true and correct in all respects) at and as of the Subscription
Closing as though made on the date of the Subscription Closing (except for those representations and warranties that speak as of a specific
date, which shall be so true and correct in all material respects (other than representations and warranties that are qualified as to
materiality or Material Adverse Effect, which representations and warranties shall be true and correct in all respects) as of such specified
date), but in each case without giving effect to the Transaction Closing (except as otherwise provided herein) (collectively, the “Company
Bring-Down Condition”), and the Company agrees that consummation of the Subscription Closing shall constitute a certification
by the Company to the Subscriber that the Company Bring-Down Condition has been satisfied;

 

    3

    

    

 

		ii.	the Company shall have performed, satisfied, or complied in all material respects with all agreements,
conditions and covenants required by this Subscription Agreement;

 

		iii.	no amendment, modification or waiver of the Transaction Agreement (as defined below) from and after the
date hereof shall have occurred that reasonably would be expected to materially and adversely affect the economic benefits that the Subscriber
reasonably would expect to receive under this Subscription Agreement without having received the Subscriber’s prior written consent;

 

		iv.	the Company shall have filed with the NYSE (as defined below) an application or supplemental listing application
for the listing of the Shares and the Shares shall have been approved for listing, subject to official notice of issuance;

 

		v.	all consents, waivers, authorizations or orders of, any notice required to be made to, and any filing
or registration with, any court or other federal, state, local or other governmental authority, self-regulatory organization (including
the NYSE and any stockholder approval required by the rules and regulations of the NYSE) or other person in connection with the execution,
delivery and performance of this Subscription Agreement (including, without limitation, the issuance of the Shares) required to be made
in connection with the issuance and sale of the Shares shall have been obtained or made, except where the failure to so obtain or make
would not prevent the Company from consummating the transactions contemplated hereby, including the issuance and sale of the Shares; and

 

		vi.	vii. there shall not have occurred any Material Adverse Effect.

 

c. The
obligations of each of the Company and the Subscriber to consummate the transactions contemplated hereunder are subject to the conditions
that, at the Subscription Closing:

 

		i.	no governmental authority shall have enacted, issued, promulgated, enforced or entered any judgment, order,
law, rule or regulation (whether temporary, preliminary or permanent) which is then in effect and has the effect of making consummation
of the transactions contemplated hereby illegal or otherwise restraining or prohibiting consummation of the transactions contemplated
hereby, and no governmental authority shall have instituted or threatened in writing a proceeding seeking to impose any such restraint
or prohibition;

 

		ii.	all conditions precedent to the Transaction Closing set forth in the Transaction Agreement, including
the approval of the Company’s stockholders and regulatory approvals, if any, shall have been satisfied or waived (other than those
conditions which, by their nature, are to be satisfied by a party to the Transaction Agreement at the Transaction Closing, but subject
to satisfaction or waiver by such party of such conditions as of the Transaction Closing) and the closing of the Transaction shall be
scheduled to occur substantially concurrently with or immediately following the Closing;

 

    4

    

    

 

		iii.	the subscriptions contemplated by the Other Subscription Agreements executed by the Other Subscribers
shall have been or will be consummated substantially concurrently with the Closing; and

 

		iv.	no suspension of the qualification of the Shares
for offering or trading in any jurisdiction, or initiation or written threats of any proceedings for any of such purposes, shall have
occurred and be continuing.

 

		d.	Prior to or at the Subscription Closing, Subscriber shall deliver to the Company a duly completed and
executed Internal Revenue Service Form W-9 or appropriate Form W-8.

 

4. Further
Assurances. At the Subscription Closing, the parties hereto shall execute and deliver or cause to be executed and delivered such additional
documents and take such additional actions as the parties reasonably may deem to be practical and necessary in order to consummate the
subscription as contemplated by this Subscription Agreement.

 

5. Company
Representations and Warranties. The Company represents and warrants to the Subscriber that:

 

a. The
Company is validly existing and is in good standing under the laws of the State of Delaware, with corporate power and authority to own,
lease and operate its properties and conduct its business as presently conducted and to enter into, deliver and perform its obligations
under this Subscription Agreement and the Transaction Agreement. VNNA Merger Sub Corp. (“Merger Sub”) is the only subsidiary
of the Company. Except for Merger Sub, the Company does not directly or indirectly own any equity or similar interest in, or any interest
convertible into or exchangeable or exercisable for any equity or similar interest in, any corporation, partnership, joint venture or
business association or other person.

 

b. The
Shares have been duly authorized by the Company and, when issued and delivered to the Subscriber against full payment therefor in accordance
with the terms of this Subscription Agreement, the Shares will be validly issued, fully paid and non-assessable and will not have been
issued in violation of or subject to any preemptive or similar rights created under the Company’s Amended and Restated Certificate
of Incorporation or under the laws of the State of Delaware.

 

    5

    

    

 

c. As
of the date hereof, the authorized capital stock of the Company consists of (i) 1,000,000 shares of preferred stock, par value $0.0001
per share (“Preferred Stock”), (ii) 100,000,000 shares of Class A Common Stock, and (iii) 10,000,000 shares of Class
B Common Stock, par value $0.0001 per share. As of the date hereof and as of immediately prior to the Subscription Closing and the Transaction
Closing: (A) no shares of Preferred Stock are issued and outstanding, (B) 26,425,643 shares of Class A Common Stock are issued and outstanding,
(C) 7,500,000 shares of Class B Common Stock are issued and outstanding, (D) 8,000,000 private placement warrants (the “Private
Placement Warrants”) are issued and outstanding and 8,000,000 shares of Class A Common Stock are issuable in respect of such
Private Placement Warrants, (E) 16,808,520 public warrants (the “Public Warrants”) are issued and outstanding and 16,808,520
shares of Class A Common Stock are issuable in respect of such Public Warrants, and (F) 3,574,357 public units (the “Public Units”)
are issued and outstanding, 3,574,357 shares of Class A Common Stock and 1,191,452 Public Warrants are issuable in respect of such public
units, and 1,191,452 shares of Class A Common Stock are issuable in respect of such Public Warrants underlying such public units; provided,
that, to the extent the Public Units are split into their constituent shares of Class A Common Stock and Public Warrants prior to the
Subscription Closing, the number of outstanding Public Units will decrease by the number of Public Units split, the number of shares of
Class A Common Stock outstanding will increase by the number of Public Units split, and the number of Public Warrants outstanding will
increase by one-third of the number of Public Units split. Each Private Placement Warrant and Public Warrant is exercisable for one share
of Class A Common Stock at an exercise price of $11.50 per share. No Private Placement Warrants or Public Warrants are exercisable on
or prior to the Transaction Closing. All (i) issued and outstanding shares of Class A Common Stock and Class B Common Stock have been
duly authorized and validly issued, are fully paid and non-assessable and are not subject to preemptive rights and (ii) outstanding Private
Placement Warrants and Public Warrants have been duly authorized and validly issued, are fully paid and are not subject to preemptive
rights. As of the date hereof, except for Merger Sub (formed for purposes of effecting the Transaction), the Company has no subsidiaries
and does not own, directly or indirectly, interests or investments (whether equity or debt) in any person, whether incorporated or unincorporated.
As of the date hereof, except as set forth above and pursuant to (i) the Other Subscription Agreements, (ii) the NM Subscription Agreement
and the other agreements entered into with NM and its affiliates in connection with the Transactions (the “NM Agreements”),or
(iii) the Transaction Agreement, there are no outstanding options, warrants or other rights to subscribe for, purchase or acquire from
the Company any shares of Common Stock, Preferred Stock or other equity interests in the Company (collectively, “Equity Interests”)
or securities convertible into or exchangeable or exercisable for Equity Interests. There are no securities or instruments issued by or
to which the Company is a party containing anti-dilution or similar provisions that will be triggered by the issuance of (i) the Shares
or (ii) the shares of Common Stock to be issued pursuant to any Other Subscription Agreement or the NM Subscription Agreement, in each
case, that have not been or will not be validly waived on or prior to the Subscription Closing; except, in certain circumstances, as provided
in the Private Placement Warrants and the Public Warrants pursuant to that certain Warrant Agreement, dated as of October 20, 2020, between
the Company and Continental Stock Transfer & Trust Co. Other than the NM Agreements, there are no stockholder agreements, voting trusts
or other agreements or understandings to which the Company is a party or by which it is bound relating to the voting of any Equity Interests,
other than as contemplated by the Transaction Agreement. There are no outstanding contractual obligations of the Company to provide funds
to, or make any investment (in the form of a loan, capital contribution or otherwise) in, any other person or entity.

 

d. The
Shares are not, and following the Transaction Closing and the Subscription Closing will not be, subject to any Transfer Restriction. The
term “Transfer Restriction” means any condition to or restriction on the ability of the Subscriber to pledge, sell,
assign or otherwise transfer the Shares under any organizational document, policy or agreement of, by or with the Company, but excluding
the restrictions on transfer described in paragraph 6(c) of this Subscription Agreement with respect to the status of the Shares as “restricted
securities” pending their registration for resale or transfer under the Securities Act in accordance with applicable securities
laws.

 

    6

    

    

 

e. This
Subscription Agreement and the Transaction Agreement have been duly authorized, executed and delivered by the Company and, assuming, with
respect to this Subscription Agreement, the due authorization, execution and delivery of the same by the Subscriber, this Subscription
Agreement and the Transaction Agreement are the legally binding obligations of the Company and are enforceable in accordance with their
respective terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium or other laws relating to or affecting the rights of creditors generally, or (ii) principles of equity, whether considered
at law or equity.

 

f. The
execution, delivery and performance of the Subscription Agreement and the Transaction
Agreement, the issuance and sale of the Shares pursuant to this Subscription Agreement and the compliance by the Company with all
of the provisions of this Subscription Agreement and the Transaction Agreement and the consummation of the transactions herein and therein
will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result
in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of the Company or any of its subsidiaries
pursuant to the terms of (i) any indenture, mortgage, deed of trust, loan or credit agreement, guarantee,
note, bond, permit, lease, license or other agreement or instrument to which the Company or any of its subsidiaries is a party
or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company is subject, which
would reasonably be expected to have a material adverse effect on the business, properties, management, financial condition, stockholders’
equity or results of operations of the Company and its subsidiaries, taken as a whole or materially affect the validity of the Shares
or the legal authority or ability of the Company to timely comply with the terms of this Subscription Agreement or the Transaction Agreement,
including the issuance and sale of the Shares (a “Material Adverse Effect”); (ii) result in any violation of the provisions
of the organizational documents of the Company; or (iii) result in any violation of any statute or any judgment, order, rule or regulation
of any court or governmental agency, taxing authority or regulatory body, domestic or foreign, having jurisdiction over the Company or
any of its properties that would reasonably be expected to have a Material Adverse Effect.

 

g. Assuming
the accuracy of the representations and warranties of the Subscriber set forth in Section 6 of this Subscription Agreement, the
Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration
with, any court or other federal, state, local or other governmental authority, self-regulatory organization (including the New York Stock
Exchange (“NYSE”)) or other person in connection with the execution, delivery and performance of this Subscription
Agreement or the Transaction Agreement (including, without limitation, the issuance of the Shares pursuant to this Subscription Agreement),
other than (i) filings with the Securities and Exchange Commission (the “Commission”), (ii) filings required by applicable
state securities laws, (iii) filings required by NYSE, including with respect to obtaining shareholder approval, (iv) filings required
to consummate the Transaction as provided under the definitive documents relating to the Transaction, (v) the filing of a notification
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, if applicable, and (vi) where the failure of which to obtain would not
reasonably be expected to have a Material Adverse Effect.

 

    7

    

    

 

h. The
Company is in compliance with all applicable law, except where such non-compliance would not reasonably be expected to have a Material
Adverse Effect. The Company has not received any written communication from a governmental entity that alleges that the Company is not
in compliance with or is in default or violation of any applicable law, except where such non-compliance, default or violation would not
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

i. The
issued and outstanding shares of Common Stock of the Company are registered pursuant to Section 12(b) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), and are listed for trading on NYSE under the symbol “XPOA”
(it being understood that the trading symbol will be changed in connection with the Transaction Closing). There is no suit, action, proceeding
or investigation pending or, to the knowledge of the Company, threatened against the Company by NYSE or the Commission, respectively,
to prohibit or terminate the listing of the Common Stock on NYSE or to deregister the Common Stock under the Exchange Act. The Company
has taken no action that is designed to terminate the registration of the Common Stock under the Exchange Act. Upon consummation of the
Transaction, the issued and outstanding shares of Class A Common Stock, including the Shares to be issued pursuant to this Subscription
Agreement, will be registered pursuant to Section 12(b) of the Exchange Act and will be listed for trading on the NYSE.

 

j. Assuming
the accuracy of the Subscriber’s representations and warranties set forth in Section 6 of this Subscription Agreement, no registration
under the Securities Act is required for the offer and sale of the Shares by the Company to the Subscriber. The Shares (i) were not offered
by any form of general solicitation or general advertising (within the meaning of Regulation D) and (ii) are not being offered in a manner
involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws.

 

k. The
Company has timely made all filings, reports, statements, schedules, prospectuses, registration statements and other documents, if any,
required to be filed by it with the Commission since its initial registration of its Common Stock with the Commission (the “SEC
Documents”). A copy of each SEC Document is available to the Subscriber via the Commission’s EDGAR system, which SEC Documents,
as of their respective filing dates, complied in all material respects with the requirements of the Exchange Act applicable to the SEC
Documents and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents. Except as to the Warrant Accounting
Matter (as hereinafter defined), none of the SEC Documents contained, when filed or, if amended, as of the date of such amendment with
respect to those disclosures that are amended, any untrue statement of a material fact or omitted to state a material fact required to
be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The Company has timely filed each report, statement, schedule, prospectus, and registration statement that the Company was required to
file with the Commission since its initial registration of the Common Stock under the Exchange Act (giving effect to permissible extensions
in accordance with Rule 12b-25 under the Exchange Act). Except as to the Warrant Accounting Matter, the financial statements of the Company
included in the SEC Documents comply in all material respects with applicable accounting requirements and the rules and regulations of
the Commission with respect thereto as in effect at the time of filing and fairly present in all material respects the financial position
of the Company as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the
case of unaudited statements, to normal, year-end audit adjustments. Notwithstanding anything herein to the contrary, the Company has
not yet performed an analysis of the possible impact to the SEC Documents of the recent statement by the staff of the Division of Corporation
Finance of the Commission (the “Staff”) on accounting and reporting considerations for warrants issued by special purpose
acquisition companies or whether any of the Company’s financial statements included in the SEC Documents will be restated as a result
of such Staff statement (the “Warrant Accounting Matter”). As of the date hereof and upon the Transaction Closing Date,
there are no material outstanding or unresolved comments in comment letters from the Staff of the Commission with respect to any of the
SEC Documents.

 

    8

    

    

 

l. Except
for such matters as have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect,
there is no (i) action, suit, claim or other proceeding, in each case by or before any governmental authority pending, or, to the knowledge
of the Company, threatened against the Company or (ii) judgment, decree, injunction, ruling or order of any governmental entity or arbitrator
outstanding against the Company.

 

m. The
Company acknowledges and agrees that, notwithstanding anything herein to the contrary, the Shares may be pledged by the Subscriber in
connection with a bona fide margin agreement, which shall not be deemed to be a transfer, sale or assignment of the Shares hereunder,
and the Subscriber effecting a pledge of Shares shall not be required to provide the Company with any notice thereof or otherwise make
any delivery to the Company pursuant to this Subscription Agreement; provided that such pledge shall be (i) pursuant to an available exemption
from the registration requirements of the Securities Act or (ii) pursuant to, and in accordance with, a registration statement that is
effective under the Securities Act at the time of such pledge, and the Subscriber effecting a pledge of Shares shall not be required to
provide the Company with any notice thereof.

 

n. Neither
the Company, nor any person acting on its behalf has, directly or indirectly, made any offers or sales of any Company security or solicited
any offers to buy any Company security under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) of the
Securities Act for the exemption from registration of the offer and sale of the Shares or would require registration of the issuance of
the Shares under the Securities Act.

 

o. Each
of the Company, Merger Sub, and of their respective directors and officers, and to Company’s knowledge, Old Jam City and New Jam
City and any of their directors and officers are not (i) a person or entity named on the List of Specially Designated Nationals and Blocked
Persons administered by the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”) or in any Executive
Order issued by the President of the United States and administered by OFAC (“OFAC List”), or a person or entity prohibited
by any OFAC sanctions program, or (ii) a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515.

 

    9

    

    

 

p. The
Company is not, and immediately after receipt of payment for the Shares will not be, an “investment company” within the meaning
of the Investment Company Act of 1940, as amended.

 

6. Subscriber
Representations and Warranties. The Subscriber represents and warrants to the Company that:

 

a. The
Subscriber is an “accredited investor” (within the meaning of Rule 501(a) under the Securities Act), satisfying the requirements
set forth on Schedule A, and is acquiring the Shares only for his, her or its own account and not for the account of others, and
not on behalf of any other account or person or with a view to, or for offer or sale in connection with, any distribution thereof in violation
of the Securities Act (and shall provide the requested information on Schedule A following the signature page hereto).

 

b. The
Subscriber understands that the Shares are being offered in a transaction not involving any public offering within the meaning of the
Securities Act and that the Shares have not been registered under the Securities Act. The Subscriber understands that the Shares may not
be resold, transferred, pledged or otherwise disposed of by the Subscriber absent an effective registration statement under the Securities
Act except (i) to the Company or a subsidiary thereof, (ii) pursuant to offers and sales that qualify as “offshore transactions”
within the meaning of Regulation S under the Securities Act or (iii) pursuant to another applicable exemption from the registration requirements
of the Securities Act (including, without limitation, a private resale or transfer pursuant to the so-called “Section 4(a)(11⁄2)”
exemption), and in each of cases (i) and (iii) in accordance with any applicable securities laws of the states and other jurisdictions
of the United States, and that any certificates or book-entry positions representing the Shares shall contain a legend to such effect.
The Subscriber acknowledges that the Shares will not be immediately eligible for resale or transfer pursuant to Rule 144 promulgated under
the Securities Act, that Rule 144 will not be available until 12 months following the closing and, as a result, the Subscriber may not
be able to readily resell or transfer the Shares and may be required to bear the financial risk of an investment in the Shares for an
indefinite period of time. The Subscriber understands that it has been advised to consult legal counsel prior to making any offer, resale,
pledge or transfer of any of the Shares.

 

c. The
Subscriber understands and agrees that the Subscriber is purchasing Shares directly from the Company. The Subscriber further acknowledges
that there have been no representations, warranties, covenants and agreements made to the Subscriber by the Company, its officers or directors,
or any other party to the Transaction or person or entity, expressly or by implication, other than those representations, warranties,
covenants and agreements included in this Subscription Agreement.

 

d. The
Subscriber acknowledges and agrees that the Subscriber has received and has had an adequate opportunity to review, such financial and
other information as the Subscriber deems necessary in order to make an investment decision with respect to the Shares and made its own
assessment and is satisfied concerning the relevant tax and other economic considerations relevant to the Subscriber’s investment
in the Shares. Without limiting the generality of the foregoing, the Subscriber acknowledges that it has reviewed the risk factors provided
to the Subscriber by the Company. The Subscriber represents and agrees that the Subscriber and the Subscriber’s professional advisor(s),
if any, have had the opportunity to ask such questions, receive such answers and obtain such information as the Subscriber and such Subscriber’s
professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Shares. The Subscriber further
acknowledges that the information provided to the Subscriber is preliminary and subject to change and the Company is under no obligation
to inform the Subscriber regarding any such changes, except to the extent such changes would reasonably be expected to cause the failure
of the Company to satisfy a condition to the Subscriber’s obligations at the Subscription Closing.

 

    10

    

    

 

e. The
Subscriber acknowledges and agrees that the Company continues to review the Warrant Accounting Matter and its implications, including
on the financial statements and other information included in its filings with the Commission, and any restatement, revision or other
modification of such filings relating to or arising from such review, any subsequent related agreements or other guidance from the Staff
shall be deemed not material for purposes of this Subscription Agreement.

 

f. The
Subscriber became aware of this offering of the Shares solely by means of direct contact between the Subscriber and the Company or a representative
of the Company, and the Shares were offered to the Subscriber solely by direct contact between the Subscriber and the Company or a representative
of the Company. The Subscriber did not become aware of this offering of the Shares, nor were the Shares offered to the Subscriber, by
any other means. The Subscriber acknowledges that the Company’s representation and warranty that the Shares (i) were not offered
by any form of general solicitation or general advertising and (ii) are not being offered in a manner involving a public offering under,
or in a distribution in violation of, the Securities Act, or any state securities laws.

 

g. The
Subscriber acknowledges that it is aware that there are substantial risks incident to the purchase and ownership of the Shares. The Subscriber
is able to fend for himself, herself or itself in the transactions completed herein, has such knowledge and experience in financial and
business matters as to be capable of evaluating the merits and risks of an investment in the Shares and has the ability to bear the economic
risks of such investment in the Shares and can afford a complete loss of such investment. The Subscriber has sought such accounting, legal
and tax advice as the Subscriber has considered necessary to make an informed investment decision.

 

h. Alone,
or together with any professional advisor(s), the Subscriber has adequately analyzed and fully considered the risks of an investment in
the Shares and determined that the Shares are a suitable investment for the Subscriber and that the Subscriber is able at this time and
in the foreseeable future to bear the economic risk of a total loss of the Subscriber’s investment in the Company. The Subscriber
acknowledges specifically that a possibility of total loss exists.

 

i. In
making its decision to purchase the Shares, the Subscriber has relied solely upon independent investigation made by the Subscriber and
the representations, warranties and covenants contained herein. Subscriber acknowledges and agrees that Subscriber had access to, and
an adequate opportunity to review, financial and other information as Subscriber deems necessary in order to make an investment decision
with respect to the Shares.

 

    11

    

    

 

j. The
Subscriber understands and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of the Shares
or made any findings or determination as to the fairness of this investment.

 

k. If
the Subscriber is an entity, the Subscriber is validly existing in good standing under the laws of its jurisdiction of incorporation or
formation, with power and authority to enter into and perform its obligations under this Subscription Agreement. If the Subscriber is
an individual, the Subscriber has the legal capacity to enter into and perform his or her obligations under this Subscription Agreement.

 

l. The
execution, delivery and performance by the Subscriber of this Subscription Agreement are within the powers of the Subscriber, and if the
Subscriber is not an individual, have been duly authorized and will not constitute or result in a breach or default under or conflict
with any order, ruling or regulation of any court or other tribunal or of any governmental commission or agency, or any agreement or other
undertaking, to which the Subscriber is a party or by which the Subscriber is bound which would reasonably be expected to have a material
adverse effect on the legal authority or ability of the Subscriber to enter into and perform its obligation under this Subscription Agreement,
and, if the Subscriber is not an individual, will not violate any provisions of the Subscriber’s charter documents, including, without
limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable.
The signature on this Subscription Agreement is genuine, and the signatory, if the Subscriber is an individual, has legal competence and
capacity to execute the same or, if the Subscriber is not an individual, the signatory has been duly authorized to execute the same, and
assuming the due authorization, execution and delivery of the same by the Company, this Subscription Agreement constitutes a legal, valid
and binding obligation of the Subscriber, enforceable against the Subscriber in accordance with its terms, except as may be limited or
otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting
the rights of creditors generally, or (ii) principles of equity, whether considered at law or equity.

 

m. Neither
the due diligence investigation conducted by the Subscriber in connection with making its decision to acquire the Shares nor any representations
and warranties made by the Subscriber herein shall modify, amend or affect the Subscriber’s right to rely on the truth, accuracy
and completeness of the Company’s representations and warranties contained herein.

 

n. The
Subscriber is not (i) a person or entity named on the OFAC List, or a person or entity prohibited by any OFAC sanctions program, (ii)
a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515, or (iii) a non-U.S. shell bank or providing
banking services indirectly to a non-U.S. shell bank. The Subscriber agrees to provide law enforcement agencies, if requested thereby,
such records as required by applicable law, provided that the Subscriber is permitted to do so under applicable law. If the Subscriber
is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section 5311 et seq.), as amended by the USA PATRIOT Act of 2001,
and its implementing regulations (collectively, the “BSA/PATRIOT Act”), to the extent required, the Subscriber maintains
policies and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act.  To the extent required,
it maintains policies and procedures reasonably designed for the screening of its investors against the OFAC sanctions programs, including
the OFAC List. To the extent required, it maintains policies and procedures reasonably designed to ensure that the funds held by the Subscriber
and used to purchase the Shares were legally derived.

 

o. As
of the date of this Subscription Agreement the Subscriber does not have, and during the thirty (30) day period immediately prior to the
date of this Subscription Agreement the Subscriber has not entered into, any “put equivalent position” as such term is defined
in Rule 16a-1 under the Exchange Act or Short Sale positions with respect to the securities of the Company. For purposes of this Section
6 and Section 11, “Short Sales” shall include, without limitation, all “short sales” as defined in Rule
200 promulgated under Regulation SHO under the Exchange Act, and all types of direct and indirect stock pledges (other than pledges in
the ordinary course of business as part of prime brokerage arrangements), forward sale contracts, options, puts, calls, swaps and similar
arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker dealers or foreign regulated
brokers. Notwithstanding the foregoing, in case the Subscriber is a multimanaged investment vehicle whereby separate portfolio managers
manage separate portions of such Subscriber’s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Subscription Agreement.

 

    12

    

    

 

p. Subscriber
will have sufficient funds to pay the Purchase Price at the Subscription Closing.

 

q. The
Subscriber acknowledges that UBS Securities LLC or Raine Securities LLC (collectively, the “Placement Agents”) are
acting as Placement Agents in connection with the sale of the Shares to institutional accredited investors (within the meaning of Rule
501(a)) and qualified institutional buyers (as defined under the Securities Act), but not in connection with sales to any other buyers.

 

r. If
the Subscriber is a resident of Canada, the Subscriber hereby declares, represents, warrants and agrees as set forth in the attached Schedule
B.

 

7. Registration
Rights.

 

a. The
Company agrees that, within 30 calendar days after the Subscription Closing (the “Filing Deadline”), the Company will
file with the Commission (at the Company’s sole cost and expense) a registration statement (the “Registration Statement”)
registering the resale or transfer of the Shares, and the Company shall use its commercially reasonable efforts to have the Registration
Statement declared effective as soon as practicable after the filing thereof, but no later than the earlier of (i) the 60th
calendar day (or if the Commission notifies the Company that it will “review” the Registration Statement, 90th
calendar day) following the Subscription Closing, and (ii) the 5th business day after the date the Company is notified (orally
or in writing, whichever is earlier) by the Commission that the Registration Statement will not be “reviewed” or will not
be subject to further review (such earlier date, the “Effectiveness Date”); provided, however, that the Company’s
obligations to include the Shares in the Registration Statement are contingent upon the Subscriber furnishing in writing to the Company
such information regarding the Subscriber, the securities of the Company held by the Subscriber and the intended method of disposition
of the Shares as shall be reasonably requested by the Company to effect the registration of the Shares, and shall execute such documents
in connection with such registration as the Company may reasonably request that are customary of a selling stockholder in similar situations.
Notwithstanding the foregoing, if the Commission prevents the Company from including in the Registration Statement any or all of the Shares
due to limitations on the use of Rule 415 of the Securities Act for the resale or transfer of the Shares by the applicable stockholders
or otherwise (and notwithstanding that the Company used diligent efforts to advocate with the staff of the Commission for the registration
of all or a greater portion of the Shares) (a “Rule 415 Cutback”), the Registration Statement shall register for resale
or transfer such number of Shares which is equal to the maximum number of Shares as is permitted by the Commission. In such event, the
number of Shares to be registered for each selling stockholder named in the Registration Statement shall be reduced pro rata among all
such selling stockholders. If the Commission requests that the Subscriber be identified as a statutory underwriter in the Registration
Statement, the Subscriber will have an opportunity to withdraw from the Registration Statement, and, as promptly as practicable after
being permitted to register additional Shares under Rule 415 under the Securities Act, the Company shall amend the Registration Statement
or file one or more new Registration Statement(s) (such amendment or new Registration Statement shall also be deemed to be “Registration
Statement” hereunder) to register such additional Shares and cause such Registration Statement to become effective as promptly as
practicable after the filing thereof, but in any event no later than 30 calendar days after the filing of such Registration Statement
(the “Additional Effectiveness Date”); provided, that the Additional Effectiveness Date shall be extended to
60 calendar days after the filing of such Registration Statement if the Commission notifies the Company that it will “review”
such Registration Statement; provided, further the Company shall have such Registration Statement declared effective within
5 business days after the date the Company is notified in writing by the Commission that such Registration Statement will not be “reviewed”
or will not be subject to further review. The Company will use its commercially reasonable efforts to maintain the continuous effectiveness
of the Registration Statement until the earliest of (i) the date on which such Shares have actually been sold and (ii) the date which
is three years after the later of (A) the Effectiveness Date and (B) if there is a Rule 415 Cutback, the Additional Effectiveness Date.
For purposes of clarification, any failure by the Company to file the Registration Statement by the Filing Deadline or to effect such
Registration Statement by the Effectiveness Date (or any Additional Effectiveness Date) shall not otherwise relieve the Company of its
obligations to file or effect the Registration Statement set forth in this Section 7. Upon notification by the Commission that any Registration
Statement has been declared effective by the Commission, within two (2) business days thereafter, the Company shall file the final prospectus
under Rule 424 of the Securities Act. The Company shall provide a draft of the Registration Statement to Subscriber for review at least
two (2) business days in advance of filing of the Registration Statement, and Subscriber shall provide any comments on the Registration
Statement to the Company no later than the day immediately preceding the filing of the Registration Statement. In no event shall Subscriber
be identified as a statutory underwriter in the Registration Statement; provided, that if the Commission requires that the Subscriber
be identified as a statutory underwriter in the Registration Statement, the Subscriber will have the option, in its sole and absolute
discretion, to either (i) have the opportunity to withdraw from the Registration Statement upon its prompt written request to the Company,
in which case the Company’s obligation to register the Shares will be deemed satisfied or (ii) be included as such in the Registration
Statement.

 

    13

    

    

 

b. Notwithstanding
anything to the contrary in this Subscription Agreement, the Company shall be entitled to delay or postpone the effectiveness of the Registration
Statement, and from time to time to require the Subscriber not to sell under the Registration Statement or to suspend the effectiveness
thereof, if the negotiation or consummation of a transaction by the Company or its subsidiaries is pending, an event has occurred or circumstances
exist, which negotiation, consummation, event or circumstances, the Company’s CEO, CFO or General Counsel reasonably believes, upon
the advice of outside legal counsel, would require additional disclosure by the Company in the Registration Statement of material information
that the Company has a bona fide business purpose for keeping confidential and the non-disclosure of which in the Registration Statement
would be expected, in the reasonable determination of the Company’s CEO, CFO or General Counsel, upon the advice of outside legal
counsel, to cause the Registration Statement to fail to comply with applicable disclosure requirements (each such circumstance, a “Suspension
Event”); provided, however, that the Company may not delay or suspend the Registration Statement on more than 2 occasions or
for more than 60 consecutive calendar days, or more than 90 total calendar days, in each case during any twelve-month period. Upon receipt
of any written notice from the Company of the happening of any Suspension Event (which notice shall not contain material non-public information
and which notice shall not subject the Subscriber to any duty of confidentiality) during the period that the Registration Statement is
effective or if as a result of a Suspension Event the Registration Statement or related prospectus contains any untrue statement of a
material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made (in the case of the prospectus) not misleading, the Subscriber agrees that it will promptly
discontinue offers and sales of the Shares under the Registration Statement (excluding, for the avoidance of doubt, sales conducted pursuant
to Rule 144) until the Subscriber receives copies of a supplemental or amended prospectus (which the Company agrees to promptly prepare)
that corrects the misstatement(s) or omission(s) referred to above and receives notice that any post-effective amendment has become effective
or unless otherwise notified by the Company that it may resume such offers and sales (which notice shall not contain any material, nonpublic
information or subject the Subscriber to any duty of confidentiality). If so directed by the Company, the Subscriber will deliver to the
Company or, in the Subscriber’s sole discretion destroy, all copies of the prospectus covering the Shares in the Subscriber’s
possession; provided, however, that this obligation to deliver or destroy all copies of the prospectus covering the Shares shall not apply
(i) to the extent the Subscriber is required to retain a copy of such prospectus (a) in order to comply with applicable legal, regulatory,
self-regulatory or professional requirements or (b) in accordance with a bona fide pre-existing document retention policy or (ii) to copies
stored electronically on archival servers as a result of automatic data back-up. Notwithstanding anything to the contrary, the Company
shall cause its transfer agent to deliver unlegended shares of Class A Common Stock to a transferee of the Subscriber in connection with
any sale of Shares with respect to which the Subscriber has entered into a contract for sale, prior to the Subscriber’s receipt
of the notice of a Suspension Event and for which the Subscriber has not yet settled.

 

    14

    

    

 

c. In
the case of the registration, qualification, exemption or compliance effected by the Company pursuant to this Subscription Agreement,
the Company shall, upon reasonable request, inform the Subscriber as to the status of such registration, qualification, exemption and
compliance. At its expense the Company shall:

 

		i.	Advise the Subscriber within 5 business days:

 

		A.	when a Registration Statement or any amendment thereto has been filed with the Commission and when such
Registration Statement or any post-effective amendment thereto has become effective;

 

		B.	of any request by the Commission for amendments or supplements to any Registration Statement or the prospectus
included therein or for additional information;

 

		C.	of the issuance by the Commission of any stop order suspending the effectiveness of any Registration Statement
or the initiation of any proceedings for such purpose;

 

		D.	of the receipt by the Company of any notification with respect to the suspension of the qualification
of the Shares included therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and

 

		E.	subject to the provisions in this Subscription Agreement, of the occurrence of any event that requires
the making of any changes in any Registration Statement or prospectus so that, as of such date, the statements therein are not misleading
and do not omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of a prospectus,
in the light of the circumstances under which they were made) not misleading.

 

Notwithstanding anything to the contrary set forth
herein, the Company shall not, when so advising the Subscriber of such events, provide the Subscriber with any material, nonpublic information
regarding the Company or subject the Subscriber to any duty of confidentiality;

 

		ii.	use commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness
of any Registration Statement as soon as reasonably practicable;

 

		iii.	upon the occurrence of any Suspension Event, except for such times as the Company is permitted hereunder
to suspend, and has suspended, the use of a prospectus forming part of a Registration Statement, the Company shall use its commercially
reasonable efforts to as soon as reasonably practicable prepare a post-effective amendment to such Registration Statement or a supplement
to the related prospectus, or file any other required document so that, as thereafter delivered to purchasers of the Shares included therein,
such prospectus will not include any untrue statement of a material fact or omit to state any material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading;

 

    15

    

    

 

		iv.	until the Subscriber no longer holds any Shares, use its commercially reasonable efforts to cause all
Shares to be listed on each securities exchange or market, if any, on which the Shares issued by the Company have been listed;

 

		v.	until the Subscriber no longer holds any Shares, use its commercially reasonable efforts to take all other
steps necessary to effect the registration of the Shares contemplated hereby and to enable Subscriber to sell the Shares under Rule 144
including, but not limited to, filing all reports and other materials required to be filed by the Exchange Act to the extent the filing
of such reports and other documents is required for the applicable provisions of Rule 144 to enable Subscriber to sell the Shares under
Rule 144; and

 

		vi.	if the Shares acquired hereunder are at any time either eligible to be sold (i) pursuant to an effective
Registration Statement or (ii) without volume or manner of sale limitations under Rule 144 under the Securities Act, then at the Subscriber’s
request, the Company will take such actions necessary, in cooperation with the Company’s transfer agent (including, if required
by the Company’s transfer agent, delivering an opinion of the Company’s counsel in a form reasonably acceptable to the Company’s
transfer agent), to remove any restrictive legend set forth on such Shares so that Subscriber can move the Shares to its prime brokerage
accounts without restriction (provided that in the case of (i) above, the Subscriber will represent to transfer the Shares only pursuant
to the Company’s effective resale shelf Registration Statement on Form S-1 in a manner contemplated therein, where the Subscriber
shall deliver a representation letter to the Company’s counsel, in form and substance reasonably acceptable to Company’s counsel
(and if requested by the Company’s counsel, a representation letter from Subscriber’s prime broker) and in the case of (ii)
above, the Subscriber shall deliver a representation letter to the Company’s counsel in form and substance reasonably acceptable
to the Company’s counsel).

 

d. The
Subscriber may deliver written notice (an “Opt-Out Notice”) to the Company requesting that the Subscriber not receive
notices from the Company otherwise required by this Section 7; provided, however, that the Subscriber may later revoke any such Opt-Out
Notice in writing. Following receipt of an Opt-Out Notice from the Subscriber (unless subsequently revoked), (i) the Company shall not
deliver any such notices to the Subscriber and the Subscriber shall no longer be entitled to the rights associated with any such notice
and (ii) each time prior to the Subscriber’s intended use of an effective Registration Statement, the Subscriber will notify the
Company in writing at least two business days in advance of such intended use, and if a notice of a Suspension Event was previously delivered
(or would have been delivered but for the provisions of this Section 7(d)) and the related suspension period remains in effect, the Company
will so notify the Subscriber, within one business day of the Subscriber’s notification to the Company, by delivering to the Subscriber
a copy of such previous notice of Suspension Event, and thereafter will provide the Subscriber with the related notice of the conclusion
of such Suspension Event immediately upon its availability (which notices shall not contain any material, nonpublic information or subject
the Subscriber to any duty of confidentiality).

 

    16

    

    

 

e. The
Company shall, notwithstanding any termination of this Subscription Agreement, indemnify, defend and hold harmless the Subscriber (if
the Subscriber is named as a selling shareholder under the Registration Statement), its officers, directors, trustees, agents, partners,
members, managers, stockholders, affiliates, employees and investment advisers of each of them, and each person who controls the Subscriber
(within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) officers, directors, trustees, agents,
partners, members, managers, stockholders, affiliates, employees and investment advisers of each such controlling person to the fullest
extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation,
reasonable costs of preparation and investigation and reasonable attorneys’ fees) and expenses (collectively, “Losses”),
as incurred, that arise out of or are based upon (i) any untrue or alleged untrue statement of a material fact contained in any Registration
Statement, any prospectus included in any Registration Statement or any form of prospectus or in any amendment or supplement thereto or
in any preliminary prospectus, or arising out of or relating to any omission or alleged omission to state a material fact required to
be stated therein or necessary to make the statements therein (in the case of any prospectus or form of prospectus or supplement thereto,
in light of the circumstances under which they were made) not misleading, or (ii) any violation or alleged violation by the Company
of the Securities Act, Exchange Act or any state securities law or any rule or regulation thereunder, in connection with the performance
of its obligations under this Section 7, except to the extent, but only to the extent, that such untrue statements, alleged untrue
statements, omissions or alleged omissions are based upon information regarding the Subscriber furnished in writing to the Company by
the Subscriber expressly for use therein or the Subscriber has omitted a material fact from such information or otherwise violated the
Securities Act, Exchange Act or any state securities law or any rule or regulation thereunder; provided, however, that the indemnification
contained in this Section 7 shall not apply to amounts paid in settlement of any Losses if such settlement is effected without the consent
of the Company (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall the Company be liable for any Losses
to the extent they arise out of or are based upon a violation which occurs (A) in reliance upon and in conformity with written information
furnished by a Subscriber expressly for use in such Registration Statement, (B) in connection with any failure of such person to deliver
or cause to be delivered a prospectus made available by the Company in a timely manner to the extent required, (C) as a result of offers
or sales effected by or on behalf of any person by means of a freewriting prospectus (as defined in Rule 405 of the Securities Act) that
was not authorized in writing by the Company, or (D) in connection with any offers, sales or transfers effected by or on behalf of a Subscriber
in violation of Section 7(e) hereof. The Company shall notify the Subscriber promptly of the institution, threat or assertion of any proceeding
arising from or in connection with the transactions contemplated by this Section 7 of which the Company is aware. Such indemnity
shall remain in full force and effect regardless of any investigation made by or on behalf of an indemnified party and shall survive the
transfer of the Shares by the Subscriber.

 

f. The
Subscriber shall, severally and not jointly with any Other Subscriber or other person that is a party to any Other Subscription Agreements,
indemnify and hold harmless the Company, its directors, officers, agents and employees, and each person who controls the Company (within
the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), to the fullest extent permitted by applicable
law, from and against all Losses, as incurred, arising out of or are based upon any untrue or alleged untrue statement of a material fact
contained in any Registration Statement, any prospectus included in the Registration Statement, or any form of prospectus, or in any amendment
or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material
fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus, or any form of prospectus
or supplement thereto, in light of the circumstances under which they were made) not misleading to the extent, but only to the extent,
that such untrue statements or omissions are based upon information regarding the Subscriber furnished in writing to the Company by the
Subscriber expressly for use therein; provided, however, that the indemnification contained in this Section 7 shall not apply to amounts
paid in settlement of any Losses if such settlement is effected without the consent of the Subscriber (which consent shall not be unreasonably
withheld, conditioned or delayed). In no event shall the liability of any Subscriber be greater in amount than the dollar amount of the
net proceeds received by the Subscriber upon the sale of the Shares giving rise to such indemnification obligation. The Subscriber shall
notify the Company promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions
contemplated by this Section 7 of which the Subscriber is aware. Such indemnity shall remain in full force and effect regardless
of any investigation made by or on behalf of an indemnified party and shall survive the transfer of the Shares by the Subscriber.

 

    17

    

    

 

g. Any
person entitled to indemnification herein shall (i) give prompt written notice to the indemnifying party of any claim with respect to
which it seeks indemnification (provided that the failure to give prompt notice shall not impair any person’s right to indemnification
hereunder to the extent such failure has not prejudiced the indemnifying party) and (ii) permit such indemnifying party to assume the
defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party
shall not be subject to any liability for any settlement made by the indemnified party without its consent (but such consent shall not
be unreasonably withheld). An indemnifying party who elects not to assume the defense of a claim shall not be obligated to pay the fees
and expenses of more than one (1) counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in
the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such
indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified party, consent to
the entry of any judgment or enter into any settlement which cannot be settled in all respects by the payment of money (and such money
is so paid by the indemnifying party pursuant to the terms of such settlement) or which settlement does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim
or litigation.

 

h. If
the indemnification provided under this Section 7 from the indemnifying party is unavailable or insufficient to hold harmless an indemnified
party in respect of any Losses, then the indemnifying party, in lieu of indemnifying the indemnified party, shall contribute to the amount
paid or payable by the indemnified party as a result of such Losses in such proportion as is appropriate to reflect the relative fault
of the indemnifying party and the indemnified party, as well as any other relevant equitable considerations. The relative fault of the
indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, was made by, or relates
to information supplied by, such indemnifying party or indemnified party, and the indemnifying party’s and indemnified party’s
relative intent, knowledge, access to information and opportunity to correct or prevent such action. The amount paid or payable by a party
as a result of the Losses shall be subject to the limitations set forth in this Section 7 and deemed to include any legal or other fees,
charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution pursuant to this Section
7 from any person who was not guilty of such fraudulent misrepresentation. Each indemnifying party’s obligation to make a contribution
pursuant to this Section 7(h) shall be individual, not joint and several, and in no event shall the liability of Subscriber hereunder
exceed the net proceeds received by Subscriber upon the sale of the Shares giving rise to such indemnification obligation.

 

i. For
purposes of this Section 7, “Shares” shall mean, as of any date of determination, the Shares acquired by the Subscriber pursuant
to this Subscription Agreement and any other equity security issued or issuable with respect to such Shares by way of share split, dividend,
distribution, recapitalization, merger, exchange, replacement or similar event.

 

    18

    

    

 

8. Intentionally
Omitted.

 

9. Termination.
This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of the parties
hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earliest to occur of (a)
the termination of the definitive agreement among the Company, Old Jam City and New Jam City with respect to the Transaction dated as
of the date hereof (the “Transaction Agreement”), in accordance with its terms, (b) upon the mutual written agreement
of each of the parties hereto to terminate this Subscription Agreement, (c) if any of the conditions to the Subscription Closing
set forth in Section 3 of this Subscription Agreement are not satisfied or waived upon or prior to the Subscription Closing and,
as a result thereof, the transactions contemplated by this Subscription Agreement are not consummated at the Subscription Closing, or
(d) at the election of the Subscriber, if the Transaction Closing shall not have occurred by the Outside Date (as defined in the Transaction
Agreement as in effect on the date hereof and without giving effect to any amendment, waiver or modification to the Transaction Agreement
on and after the date hereof but giving effect to any extension of the Outside Date permitted by the Transaction Agreement as in effect
on the date hereof without any amendment, waiver or modification of the Transaction Agreement being required to effect such extension);
provided that nothing herein will relieve any party from liability for any willful breach hereof prior to the time of termination, and
each party will be entitled to any remedies at law or in equity to recover losses, liabilities or damages arising from such breach. The
Company shall promptly notify the Subscriber of the termination of the Transaction Agreement after the termination of such agreement.
For the avoidance of doubt, if any termination hereof occurs after the delivery by the Subscriber of the Purchase Price for the Shares,
the Company shall promptly (but not later than one business day thereafter) return the Purchase Price to the Subscriber without any deduction
for or on account of any tax, withholding, charges, or set-off.

 

10. Trust
Account Waiver. The Subscriber acknowledges that the Company is a special purpose acquisition company with the powers and privileges
to effect a merger, asset acquisition, reorganization or similar business combination involving the Company and one or more businesses
or assets. The Subscriber further acknowledges that, as described in the Company’s prospectus relating to its initial public offering
filed with the Commission on October 23, 2020 and available at www.sec.gov, substantially all of the Company’s assets consist of
the cash proceeds of the Company’s initial public offering and private placements of its securities, and substantially all of those
proceeds have been deposited in a trust account (the “Trust Account”) for the benefit of the Company, its public stockholders
and the underwriters of the Company’s initial public offering. For and in consideration of the Company entering into this Subscription
Agreement, the receipt and sufficiency of which are hereby acknowledged, the Subscriber hereby irrevocably waives any and all right, title
and interest, or any claim of any kind it has or may have in the future, in or to any monies held in the Trust Account, and agrees not
to seek recourse against the Trust Account, in each case, as a result of, or arising out of, this Subscription Agreement; provided that
nothing in this Section 10 shall be deemed to limit or prohibit (i) the Subscriber’s right to pursue a claim against the Company
for legal relief against assets held outside the Trust Account, for specific performance or other equitable relief, (ii) any claims that
the Subscriber may have in the future against the Company’s assets or funds that are not held in the Trust Account (including any
funds that have been released from the Trust Account and any assets that have been purchased or acquired with any such funds) or (iii)
the Subscriber’s right, title, interest or claim to the Trust Account by virtue of the Subscriber’s record or beneficial ownership
of Common Stock of the Company acquired by any means other than pursuant to this Subscription Agreement.

 

11. No
Short Sales. The Subscriber hereby agrees that, from the date of this Agreement until the Subscription Closing, none of the Subscriber,
or any person or entity acting on behalf of the Subscriber or pursuant to any understanding with the Subscriber will engage in any Short
Sales with respect to securities of the Company. Notwithstanding the foregoing, (a) nothing herein shall prohibit entities under common
management or that share an investment advisor with Subscriber (including Subscriber’s controlled affiliates and/or affiliates)
from entering into any “short sales”, (b) in the case of a Subscriber that is a multi-managed investment vehicle whereby separate
portfolio managers manage separate portions of such Subscriber’s assets, this Section 10 shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Subscription Agreement,
and (c) this Section 10 shall not apply to (x) any sale (including the exercise of any redemption right) of securities of the Company
(i) held by the Subscriber, its controlled affiliates and/or affiliates or any person or entity acting on behalf of the Subscriber or
any of its controlled affiliates and/or affiliates prior to the execution of this Subscription Agreement or (ii) purchased by the Subscriber,
its affiliates or any person or entity acting on behalf of the Subscriber or any of its controlled affiliates and/or affiliates in open
market transactions after the execution of this Subscription Agreement or (y) ordinary course, non-speculative hedging transactions so
long as the sales or borrowings relating to such hedging transactions are not settled with the Shares subscribed for hereunder and the
number of securities sold in such transactions does not exceed the number of securities owned (beneficially or of record) or subscribed
for at the time of such transactions.

 

    19

    

    

 

12. Miscellaneous.

 

a. The
Company shall, no later than 9:00 a.m., New York City time, on the first business day immediately following the date of this Subscription
Agreement, issue one or more press releases or file with the Commission a Current Report on Form 8-K (collectively, the “Disclosure
Document”) disclosing all material terms of the transactions contemplated hereby, the Transaction and any other material, nonpublic
information that the Company or any of its officers, directors, employees, affiliates or agents has provided to the Subscriber at any
time prior to the filing of the Disclosure Document. From and after the issuance of the Disclosure Document, the Subscriber shall not
be in possession of any material, non-public information received from the Company or any of its officers, directors, employees, affiliates
or agents and from the issuance of the Disclosure Document, the Subscriber shall no longer be subject to any confidentiality or similar
obligations under any current agreement, whether written or oral with the Company, any of its officers, directors, employees, affiliates
or agents, or any of their respective affiliates. Except with the express written consent of the Subscriber and unless prior thereto the
Subscriber and the Company shall have executed a written agreement regarding the confidentiality and use of such information, the Company
shall not, and shall cause its officers, directors, employees and agents, not to, provide Subscriber with any material, non-public information
regarding the Company or the Transaction from and after the filing of the Disclosure Document. The Company understands and confirms that
the Subscriber and its affiliates will rely on the foregoing representations in effecting transactions in securities of the Company. Notwithstanding
anything in this Subscription Agreement to the contrary, each party hereto acknowledges and agrees that without the prior written consent
of the other party hereto it will not (and in the case of the Company it will cause its representatives not to) publicly make reference
to such other party or any of its affiliates (i) in connection with the Transaction or this Subscription Agreement (provided that the
Subscriber may disclose its entry into this Subscription Agreement and the Purchase Price) or (ii) in any promotional materials, media,
or similar circumstances, except, in each case, as required by law or regulation or at the request of the Staff or regulatory agency or
under the regulations of NYSE, including, in the case of the Company (a) as required by the federal securities law in connection with
the Registration Statement, (b) the filing of a form of this Subscription Agreement with the Commission and (c) the filing of the Registration
Statement on Form S-4 and related proxy statement to be filed by the Company with respect to the Transaction, in which case the Company
shall provide the Subscriber with prior written notice of such disclosure permitted under this subclause (ii) and shall reasonably consult
with Subscriber regarding such disclosure.

 

b. Neither this Subscription
Agreement nor any rights that may accrue to the parties hereunder (other than the Shares acquired hereunder, if any, and the rights set
forth in Section 7) may be transferred or assigned without the prior written consent of the other party hereto; provided, that Subscriber
may transfer or assign all or a portion of its rights under this Subscription Agreement, with the Company’s consent, to another
person.

 

c. The
Company may request from the Subscriber such additional information as the Company may deem reasonably necessary to evaluate the eligibility
of the Subscriber to acquire the Shares, and the Subscriber promptly shall provide such information as may reasonably be requested, to
the extent readily available and to the extent consistent with its internal policies and procedures, provided that the Company agrees
to keep confidential any such information to the extent such information is not in the public domain, was not provided lawfully to the
Company by another source not under a duty of confidentiality and except to the extent disclosure of such information by the Company is
compelled by law, court order or a self-regulatory organization such as NYSE or FINRA or required to be included in the Registration Statement,
in which case, the Company shall provide the Subscriber with prior written notice of any disclosure of such information if reasonably
practicable and legally permitted and shall reasonably consult with Subscriber regarding such disclosure.

 

    20

    

    

 

d. The
Subscriber acknowledges that the Company and, only following the Subscription Closing and the Transaction Closing, New Jam City may rely
on the acknowledgments, understandings, agreements, representations and warranties of the Subscriber contained in this Subscription Agreement.
The Company acknowledges that the Subscriber will rely on the acknowledgements, understandings, agreements, representations and warranties
of the Company contained in this Subscription Agreement. Prior to the Subscription Closing, the Subscriber agrees to notify the Company
promptly if any of the acknowledgments, understandings, agreements, representations and warranties set forth herein are no longer accurate
in any material respect (other than those acknowledgments, understandings, agreements, representations and warranties qualified by materiality,
in which case the Subscriber shall notify the Company if they are no longer accurate in all respects). Prior to the Subscription Closing,
the Company agrees to notify the Subscriber promptly if any of the acknowledgments, understandings, agreements, representations and warranties
set forth herein are no longer accurate in any material respect (other than those acknowledgments, understandings, agreements, representations
and warranties qualified by materiality or Material Adverse Effect, in which case the Company shall notify the Subscriber if they are
no longer accurate in all respects).

 

e. The
Company and the Subscriber are entitled to rely upon this Subscription Agreement and each party hereto is irrevocably authorized to produce
this Subscription Agreement or a copy hereof when required by law, governmental authority or self-regulatory organization to do so in
any administrative or legal proceeding or official inquiry with respect to the matters covered hereby.

 

f. Except
if required by law, governmental authority or self-regulatory organization, without the prior written consent of the Subscriber, the Company
shall not, and shall cause its representatives, not to, disclose the existence of this Subscription Agreement or any negotiations related
hereto, or to use the name of the Subscriber or any information provided by the Subscriber in connection herewith in or for the purpose
of any marketing activities or materials or for any similar or related purpose.

 

g. All
the agreements, representations and warranties made by each party to this Subscription Agreement shall survive the Subscription Closing.

 

h. This
Subscription Agreement may not be modified, waived or terminated (other than pursuant to the terms of Section 9 hereof) except by an instrument
in writing, signed by the party against whom enforcement of such modification, waiver, or termination is sought; provided that any rights
(but not obligations) of a party under this Subscription Agreement may be waived, in whole or in part, by such party on its own behalf
without the prior consent of any other party.

 

    21

    

    

 

i. This
Subscription Agreement constitutes the entire agreement, and supersedes all other prior agreements, understandings, representations and
warranties, both written and oral, among the parties, with respect to the subject matter hereof. Except as otherwise expressly set forth
in subsection (d) of this Section 12 and Section 7, this Subscription Agreement shall not confer any rights or remedies upon any person
other than the parties hereto, and their respective successor and assigns.

 

j. Except
as otherwise provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the parties hereto and their
heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations, warranties,
covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs, executors, administrators,
successors, legal representatives and permitted assigns.

 

k. If
any provision of this Subscription Agreement shall be invalid, illegal or unenforceable, the validity, legality or enforceability of the
remaining provisions of this Subscription Agreement shall not in any way be affected or impaired thereby and shall continue in full force
and effect so long as this Subscription Agreement as so modified continues to express, without material change, the original intentions
of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question
does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the
benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited,
invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited,
invalid or unenforceable provision(s).

 

l. This
Subscription Agreement may be executed and delivered in one or more counterparts (including by facsimile or any other form of electronic
delivery (including .pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or other
transmission method)) and by different parties in separate counterparts, with the same effect as if all parties hereto had signed the
same document. All counterparts so executed and delivered shall be construed together and shall constitute one and the same agreement.

 

m. The
parties hereto agree that irreparable damage may occur in the event that any of the provisions of this Subscription Agreement were not
performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled
to seek equitable relief, including in the form of an injunction or injunctions to prevent breaches of this Subscription Agreement and
to enforce specifically the terms and provisions of this Subscription Agreement, this being in addition to any other remedy to which such
party is entitled to seek at law, in equity, in contract, in tort or otherwise.

 

    22

    

    

 

n. Any
notice, request, claim, demand, waiver, consent, approval or other communication which is required or permitted hereunder shall be in
writing and shall be deemed given (a) when delivered by hand (with written confirmation of receipt), (b) when received by the addressee
if sent by a nationally recognized overnight courier postage prepaid (receipt requested), (c) on the date sent by email (with no “bounceback”
or notice of non-delivery) if sent during normal business hours of the recipient, and on the next business day if sent after normal business
hours of the recipient or (d) on the third business day after the date mailed, by certified or registered mail, return receipt requested,
postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a
party as shall be specified in a notice given in accordance with this Section 12(n)):

 

		i.	if to the Subscriber, to such address or addresses set forth on the Subscriber’s signature page
hereto;

 

		ii.	if to the Company prior to the Transaction Closing, to:

 

DPCM Capital, Inc.

382 NE 191 Street, #24148

Miami, FL 33179

Attention: Emil Michael

Telephone: (305) 857-5086

 

With a required copy to (which shall not constitute notice):

 

Greenberg Traurig, LLP

MetLife Building

200 Park Avenue

New York, New York 10166

		Attention:	Alan Annex

Kevin Friedmann

		Email:	AnnexA@gtlaw.com

FriedmannK@gtlaw.com

 

		iii.	If to Jam City prior to the Transaction Closing, to:

 

Jam City, Inc.

3562 Eastham Drive

Culver City, CA 90232

Attention: Rob Zakari

Email: rob@jamcity.com

 

With a required copy to (which shall not constitute notice):

 

Fenwick & West LLP

801 California Street

Mountain View, CA 94041

		Attention:	Mark C. Stevens

James D. Evans

Katherine K. Duncan

		Email:	mstevens@fenwick.com

jevans@fenwick.com

kduncan@fenwick.com

 

    23

    

    

 

		iv.	If to the Company after the Transaction Closing, to:

 

Jam City, Inc.

3562 Eastham Drive

Culver City, CA 90232

Attention: Rob Zakari

Email: rob@jamcity.com

 

With a required copy to (which shall not constitute notice):

 

Fenwick & West LLP

801 California Street

Mountain View, CA 94041

		Attention:	Mark C. Stevens

James D. Evans

Katherine K. Duncan

		Email:	mstevens@fenwick.com

jevans@fenwick.com

kduncan@fenwick.com

 

o. THIS
SUBSCRIPTION AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE
PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD OTHERWISE REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER STATE.

 

THE PARTIES HERETO IRREVOCABLY
SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, THE SUPREME COURT OF THE
STATE OF NEW YORK AND THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA LOCATED IN THE STATE OF NEW YORK SOLELY IN RESPECT OF THE INTERPRETATION
AND ENFORCEMENT OF THE PROVISIONS OF THIS SUBSCRIPTION AGREEMENT AND THE DOCUMENTS REFERRED TO IN THIS SUBSCRIPTION AGREEMENT AND IN RESPECT
OF THE TRANSACTIONS CONTEMPLATED HEREBY, AND HEREBY WAIVE, AND AGREE NOT TO ASSERT, AS A DEFENSE IN ANY ACTION, SUIT OR PROCEEDING FOR
INTERPRETATION OR ENFORCEMENT HEREOF OR ANY SUCH DOCUMENT THAT IS NOT SUBJECT THERETO OR THAT SUCH ACTION, SUIT OR PROCEEDING MAY NOT
BE BROUGHT OR IS NOT MAINTAINABLE IN SAID COURTS OR THAT VENUE THEREOF MAY NOT BE APPROPRIATE OR THAT THIS SUBSCRIPTION AGREEMENT OR ANY
SUCH DOCUMENT MAY NOT BE ENFORCED IN OR BY SUCH COURTS, AND THE PARTIES HERETO IRREVOCABLY AGREE THAT ALL CLAIMS WITH RESPECT TO SUCH
ACTION, SUIT OR PROCEEDING SHALL BE HEARD AND DETERMINED BY SUCH A NEW YORK STATE OR FEDERAL COURT. THE PARTIES HEREBY CONSENT TO AND
GRANT ANY SUCH COURT JURISDICTION OVER THE PERSON OF SUCH PARTIES AND OVER THE SUBJECT MATTER OF SUCH DISPUTE AND AGREE THAT MAILING OF
PROCESS OR OTHER PAPERS IN CONNECTION WITH SUCH ACTION, SUIT OR PROCEEDING IN THE MANNER PROVIDED IN SECTION 12(n) OR IN SUCH OTHER MANNER
AS MAY BE PERMITTED BY LAW SHALL BE VALID AND SUFFICIENT SERVICE THEREOF.

 

    24

    

    

 

EACH PARTY ACKNOWLEDGES AND
AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED BY THIS SUBSCRIPTION AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT
OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK
TO ENFORCE THE FOREGOING WAIVER; (II) SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THE FOREGOING WAIVER; (III) SUCH PARTY
MAKES THE FOREGOING WAIVER VOLUNTARILY AND (IV) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS SUBSCRIPTION AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION 12(o).

 

p. If
any change in the Class A Common Stock shall occur between the date hereof and immediately prior to the Subscription Closing by reason
of any reclassification, recapitalization, stock split (including reverse stock split) or combination, exchange or readjustment of shares,
or any stock dividend, the number and type of Shares issued to the Subscriber and the Purchase Price shall be appropriately adjusted to
reflect such change

 

[SIGNATURE PAGES FOLLOW]

 

    25

    

    

 

IN WITNESS WHEREOF,
the undersigned has executed or caused this Subscription Agreement to be executed by its duly authorized representative as of the date
set forth below.

 

	
    Name of Investor:
	 	State/Country of Formation or Domicile:
	 	 	 
	By:	                                        	 	 
	Name:  	 	 	 
	Title: 	 	 	 
	 	 	 
	
    Name in which shares are to be registered

    (if different):
	 	Date: _______________, 2021 

	 	 	 
	Subscriber’s EIN:	 	 
	 	 	 
	Business Address-Street:	 	Mailing Address-Street (if different):
	 	 	 
	City, State, Zip:	 	City, State, Zip:
	 	 	 
	Attn: __________________	 	Attn: __________________
	 	 	 
	Telephone No.:	 	Telephone No.:
	 	 	 
	Email Address:	 	Email Address:
	 	 	 
	Number of Shares subscribed for:	 	 
	 	 	 
	Aggregate Subscription Amount: $	 	Price Per Share: $8.42

 

The above Subscriber agrees
that it shall pay the Purchase Price by wire transfer of United States dollars in immediately available funds to the account specified
by the Company in the Closing Notice.

 

[Signature Page to Subscription Agreement]

 

     

    

    

 

IN WITNESS WHEREOF, DPCM
Capital, Inc. has accepted this Subscription Agreement as of the date set forth below.

 

	 	DPCM CAPITAL, INC.
	 	 
	 	By:	               
	 	Name: 	 
	 	Title:	 

 

Date: ____________, 2021

 

[Signature Page to Subscription Agreement]

 

     

    

    

 

SCHEDULE A

ELIGIBILITY REPRESENTATIONS OF THE SUBSCRIBER

 

		A.	INDIVIDUAL / ENTITY ACCREDITED INVESTOR STATUS

(Please check the applicable
subparagraphs):

 

		☐	You are an “accredited investor” (within the meaning of Rule 501(a) under the Securities Act)
for one or more of the following reasons (Please check the applicable subparagraphs):

 

		 	☐	If you are an individual: Your individual net worth, or
joint net worth with your spouse, exceeds $1,000,000, excluding the value of your primary residence.
	 	 	 	 
		 	☐	If you are an individual: You personally have had an individual
income in excess of $200,000 in each of the two (2) most recent calendar years and you reasonably expect an income in excess of $200,000
in the current calendar year.
	 	 	 	 
		 	☐	If you are an individual: Your joint income with your spouse
is in excess of $300,000 in each of the two (2) most recent calendar years and you reasonably expect a joint income in excess of $300,000
in the current calendar year.
	 	 	 	 
		 	☐	If you are an individual: You hold at least one of the
following professional licenses in good standing: a Series 7, Series 65 or Series 82 license.
	 	 	 	 
		 	☐	If you are an individual: You are a family client (as defined
in Rule 202(a)(11)(G)–1 under the Advisers Act) whose investments are directed by a person with such knowledge and experience in
financial and business matters that such family office is capable of evaluating the merits and risks of the prospective investment (a
“qualifying family office”).
	 	 	 	 
		 	☐	If you are an entity: You are an entity in which all of
the equity owners are accredited investors (within the meaning of Rule 501(a) under the Securities Act).
	 	 	 	 
		 	☐	If you are an entity: You have total assets or investments
in excess of $5,000,000 and have not been formed for the purpose of investing in the Company.
	 	 	 	 
		 	☐	If you are a trust (other than a business trust): You have
total assets in excess of $5,000,000 which was not formed for the purpose of investing in the Company and whose decision to invest has
been directed by qualifying family office.
	 	 	 	 
		 	☐	If you are an entity, you are a family client whose investments
are directed by a qualifying family office.

 

		B.	QUALIFIED INSTITUTIONAL BUYER STATUS

(Please check the applicable
subparagraphs):

 

		1.	☐       We
are a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act).

 

    Schedule A - 1

    

    

 

		C.	INSTITUTIONAL ACCREDITED INVESTOR STATUS

(Please check the applicable
subparagraphs):

 

		1.	☐         We
are an “accredited investor” (within the meaning of Rule 501(a)(1), (2), (3), (7), (9), (12) or (13) under the Securities
Act) for one or more of the following reasons (Please check the applicable subparagraphs):

 

		 	☐	We are a bank, as defined in Section 3(a)(2) of the Securities
Act or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act, whether acting in
an individual or a fiduciary capacity.
	 	 	 	 
		 	☐	We are a broker or dealer registered under Section 15 of the Securities
Exchange Act of 1934, as amended.
	 	 	 	 
		 	☐	We are an insurance company, as defined in Section 2(a)(13) of
the Securities Act.
	 	 	 	 
		 	☐	We are an investment company registered under the Investment Company
Act of 1940, as amended (the “Investment Company Act”) or a business development company, as defined in Section 2(a)(48)
of that act.
	 	 	 	 
		 	☐	We are a Small Business Investment Company licensed by the U.S.
Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958.
	 	 	 	 
		 	☐	We are a plan established and maintained by a state, its political
subdivisions or any agency or instrumentality of a state or its political subdivisions for the benefit of its employees, if the plan
has total assets in excess of $5 million.
	 	 	 	 
		 	☐	We are an employee benefit plan within the meaning of the Employee
Retirement Income Security Act of 1974, if the investment decision is being made by a plan fiduciary, as defined in Section 3(21) of
such act, which is either a bank, savings and loan association, an insurance company, or a registered investment adviser, or if the employee
benefit plan has total assets in excess of $5 million or, if a self-directed plan, with investment decisions made solely by persons that
are accredited investors.
	 	 	 	 
		 	☐	We are a private business development company, as defined in Section
202(a)(22) of the Investment Advisers Act of 1940, as amended (the “Investment Adviser’s Act”).
	 	 	 	 
		 	☐	We are an organization described
in section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust, partnership, or limited liability
company, not formed for the specific purpose of acquiring the Securities, with total assets in excess of $5 million.
	 	 	 	 
		 	☐	We are a trust with total assets in excess of $5 million not formed
for the specific purpose of acquiring the Securities, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii)
under the Securities Act.
	 	 	 	 
		 	☐	We are an investment adviser registered pursuant to section 203 of the Investment Advisers Act or registered
pursuant to the laws of a state, or an investment adviser relying on the exemption from registering with the SEC under Section 203(l)
or (m) of the Investment Advisers Act;
	 	 	 	 
		 	☐	We are a Rural Business Investment Company as defined in Section 384A of the Consolidated Farm and Rural
Development Act;

 

    Schedule A - 2

    

    

 

		 	☐	We are a family office, as defined in Rule 202(a)(11)(G)-1 under the Investment Advisers Act, that (i)
has assets under management in excess of $5 million; (ii) is not formed for the specific purpose of acquiring the Securities and (iii)
has a person directing the prospective investment who has such knowledge and experience in financial and business matters so that the
family office is capable of evaluating the merits and risks of the prospective investment;
		 	☐	We are a family client, as defined in Rule 202(a)(11)(G)-1 under the Investment Advisers Act, of a family
office meeting the requirements of clause (d) above and whose prospective investment in the Company is directed by that family office
pursuant to clause (12)(iii) above;
		 	☐	We are an entity of a type not previously listed that is not formed for the specific purpose of acquiring
the Securities and owns investments in excess of $5 million. For purposes of this clause, “investments” means investments
as defined in Rule 2a51-1(b) under the Investment Company Act;

 

		☐	We are an entity in which all of the equity owners are institutional
accredited investors under any of the above subparagraphs.

 

		E.	AFFILIATE STATUS

(Please check the applicable
box)

 

THE SUBSCRIBER:

 

		☐	is:

 

		☐	is not:

 

an “affiliate” (as defined
in Rule 144 under the Securities Act) of the Company or acting on behalf of an affiliate of the Company.

 

This page should be
completed by the Subscriber and constitutes a part of the Subscription Agreement
 

    Schedule A - 3

    

    

 

SCHEDULE B

ELIGIBILITY REPRESENTATIONS OF THE SUBSCRIBER
(Canadian Investors Only)

 

		1.	We hereby declare, represent and warrant that:

 

		(a)	we are purchasing the Shares as principal for our own account, or are deemed to be purchasing the Shares
as principal for our own account in accordance with applicable Canadian securities laws, and not as agent for the benefit of another investor;

 

		(b)	we are residents in or subject to the laws of one of the provinces or territories of Canada;

 

		(c)	we are entitled under applicable securities laws to purchase the Shares without the benefit of a prospectus
qualified under such securities laws and, without limiting the generality of the foregoing, are both:

 

		a.	an “accredited investor” as defined in section 1.1 of National Instrument 45-106 Prospectus
Exemptions (“NI 45-106”) or section 73.3(1) of the Securities Act (Ontario) by virtue of satisfying the indicated
criterion in Section 11 below, and we are not a person created or used solely to purchase or hold securities as an “accredited investor”
as described in paragraph (m) of the definition of “accredited investor” in section 1.1 of NI 45-106; and

 

		b.	a “permitted client” as defined in section 1.1 of National Instrument 31-103 Registration
Requirements, Exemptions and Ongoing Registrant Obligations (“NI 31-103”) by virtue of satisfying the indicated criterion
in Section 12 below

 

		(d)	we have received, reviewed and understood, this Subscription Agreement and certain disclosure materials
relating to the placing of Shares in Canada and, are basing our investment decision solely on this Subscription and the materials provided
by the Company and not on any other information concerning the Company or the offering of the Shares;

 

		(e)	[omitted];

 

		(f)	we will execute and deliver within the applicable time periods all documentation as may be required by
applicable Canadian securities laws to permit the purchase of the Shares on the terms set forth herein and, if required by applicable
Canadian securities laws, will execute, deliver and file or assist the Company in obtaining and filing such reports, undertakings and
other documents relating to the purchase of the Shares as may be required by any applicable Canadian securities laws, securities regulator,
stock exchange or other regulatory authority; and

 

		(g)	neither we nor any party on whose behalf we are acting has been established, formed or incorporated solely
to acquire or permit the purchase of Shares without a prospectus in reliance on an exemption from the prospectus requirements of applicable
Canadian securities laws.

 

		2.	We are aware of the characteristics of the Shares, the risks relating to an investment therein and agree
that we must bear the economic risk of its investment in the Shares. We understand that we will not be able to resell the Shares under
applicable Canadian securities laws except in accordance with limited exemptions and compliance with other requirements of applicable
law, and we (and not the Company) are responsible for compliance with applicable resale restrictions or hold periods and will comply with
all relevant Canadian securities laws in connection with any resale of the Shares.

 

    Schedule B - 1

    

    

 

		3.	We hereby undertake to notify the Company immediately of any change to any declaration, representation,
warranty or other information relating to us set forth herein which takes place prior to the closing of the purchase of the Shares applied
for hereby.

 

		4.	We understand and acknowledge that (i) the Company is not a reporting issuer in any province or territory
in Canada and its securities are not listed on any stock exchange in Canada and there is currently no public market for the Shares in
Canada; and (ii) the Company currently has no intention of becoming a reporting issuer in Canada and the Company is not obligated to file
and has no present intention of filing a prospectus with any securities regulatory authority in Canada to qualify the resale of the Shares
to the public, or listing the Company’s securities on any stock exchange in Canada and thus the applicable restricted period or
hold period may not commence and the Shares may be subject to an unlimited hold period or restricted period in Canada and in that case
may only be sold pursuant to limited exemptions under applicable securities legislation.

 

		5.	We confirm we have reviewed applicable resale restrictions under relevant Canadian legislation and regulations
and we acknowledge that any certificates evidencing the Shares will be endorsed with a legend setting out resale restrictions under applicable
Canadian securities laws in substantially the following form:

 

“Unless permitted under securities
legislation, the holder of this security must not trade the security before the date that is four months and one day after the later of
(i) [insert distribution date], and (ii) the date the issuer became a reporting issuer in any Canadian province or territory.”

 

		6.	It is acknowledged that we should consult our own legal and tax advisors with respect to the tax consequences
of an investment in the Shares in our particular circumstances and with respect to the eligibility of the Shares for investment by us
and resale restrictions under relevant Canadian legislation and regulations, and that we have not relied on the Company or on the contents
of the disclosure materials provided by the Company, for any legal, tax or financial advice.

 

		7.	If we are a resident of Quebec, we acknowledge that it is our express wish that all documents evidencing
or relating in any way to the sale of the Shares be drawn in the English language only. Si nous sommes résidents de la province
de Québec, nous reconnaissons par les présentes que c’est notre volonté expresse que tous les documents faisant
foi ou se rapportant de quelque manière à la vente des engagements soient rédigés en anglais seulement.

 

		8.	We understand and acknowledge that we are making the representations, warranties and agreements contained
herein with the intent that they may be relied upon by the Company and the agents in determining our eligibility to purchase the Shares,
including the availability of exemptions from the prospectus requirements of applicable Canadian securities laws in connection with the
issuance of the Shares.

 

		9.	We consent to the collection, use and disclosure of certain personal information for the purposes of meeting
legal, regulatory, self-regulatory, security and audit requirements (including any applicable tax, securities, money laundering or anti-terrorism
legislation, rules or regulations) and as otherwise permitted or required by law, which disclosures may include disclosures to tax, securities
or other regulatory or self-regulatory authorities in Canada and/or in foreign jurisdictions, if applicable, in connection with the regulatory
oversight mandate of such authorities.

 

    Schedule B - 2

    

    

 

		10.	If we are an individual resident in Canada, we acknowledge that: (A) the Company or the agents may be
required to provide personal information pertaining to us as required to be disclosed in Schedule I of Form 45-106F1 Report of Exempt
Distribution (“Form 45-106F1”) under NI 45-106 (including its name, email address, address, telephone number and the aggregate
purchase price paid by the purchaser) (“personal information”) to the securities regulatory authority or regulator in the
local jurisdiction (the “Regulator”); (B) the personal information is being collected indirectly by the Regulator under the
authority granted to it in securities legislation; and (C) the personal information is being collected for the purposes of the administration
and enforcement of the securities legislation; and by purchasing the securities, we shall be deemed to have authorized such indirect collection
of personal information by the Regulator. Questions about the indirect collection of information should be directed to the Regulator in
the local jurisdiction, using the contact information set out below:

 

		(a)	in Alberta, the Alberta Securities Commission, Suite 600, 250 - 5th Street SW, Calgary, Alberta T2P 0R4,
Telephone: (403) 297-6454, toll free in Canada: 1-877-355-0585, Email: inquiries@asc.ca;

 

		(b)	in British Columbia, the British Columbia Securities Commission, P.O. Box 10142, Pacific Centre, 701 West
Georgia Street, Vancouver, British Columbia V7Y 1L2, Inquiries: (604) 899-6500, toll free in Canada: 1-800-373-6393, Email: inquiries@bcsc.bc.ca;

 

		(c)	in Manitoba, The Manitoba Securities Commission, 500 - 400 St. Mary Avenue, Winnipeg, Manitoba R3C 4K5,
Telephone: (204) 945-2548, toll free in Manitoba 1-800-655-5244, Email: securities@gov.mb.ca;

 

		(d)	in New Brunswick, Financial and Consumer Services Commission (New Brunswick), 85 Charlotte Street, Suite
300, Saint John, New Brunswick E2L 2J2, Telephone: (506) 658-3060, toll free in Canada: 1-866-933-2222, Email: info@fcnb.ca;

 

		(e)	in Newfoundland and Labrador, Government of Newfoundland and Labrador, Office of Superintendent of Securities,
P.O. Box 8700, Confederation Building, 2nd Floor, West Block, Prince Philip Drive, St. John’s, Newfoundland and Labrador, A1B 4J6,
Telephone: (709) 729-4189;

 

		(f)	in the Northwest Territories, the Government of the Northwest Territories, Office of the Superintendent
of Securities, P.O. Box 1320, Yellowknife, Northwest Territories X1A 2L9, Attention: Superintendent of Securities, Telephone: (867) 767-9305;

 

		(g)	in Nova Scotia, the Nova Scotia Securities Commission, Suite 400, 5251 Duke Street, Duke Tower, P.O. Box
458, Halifax, Nova Scotia B3J 2P8, Telephone: (902) 424-7768 toll free in Canada: 1-855-424-2499, Email: NSSCinquiries@novascotia.ca;

 

		(h)	in Nunavut, Government of Nunavut, Department of Justice, Legal Registries Division, P.O. Box 1000, Station
570, 1st Floor, Brown Building, Iqaluit, Nunavut X0A 0H0, Telephone: (867) 975-6590;

 

		(i)	in Ontario, the Inquiries Officer at the Ontario Securities Commission, 20 Queen Street West, 22nd Floor,
Toronto, Ontario M5H 3S8, Telephone: (416) 593-8314, toll free in Canada: 1-877-785-1555, Email: exemptmarketfilings@osc.gov.on.ca;

 

		(j)	in Prince Edward Island, the PEI Office of the Superintendent of Securities, 95 Rochford Street, 4th Floor
Shaw Building, P.O. Box 2000, Charlottetown, Prince Edward Island C1A 7N8, Telephone: (902) 368-4569;

 

		(k)	in Québec, the Autorité des marchés financiers, 800, Square Victoria, 22e étage,
C.P. 246, Tour de la Bourse, Montréal, Québec H4Z 1G3, Telephone: (514) 395-0337 or (418) 525-0337, toll free in Canada
1-877-525-0337, Email: financementdessocietes@lautorite.qc.ca (For corporate finance issuers), fonds_dinvestissement@lautorite.qc.ca (For
investment fund issuers);

 

    Schedule B - 3

    

    

 

		(l)	in Saskatchewan, the Financial and Consumer Affairs Authority of Saskatchewan, Suite 601 - 1919 Saskatchewan
Drive, Regina, Saskatchewan S4P 4H2, Telephone: (306) 787-5879, Email: fcaa@gov.sk.ca; and

 

		(m)	in Yukon, Office of the Superintendent of Securities, Government of Yukon, Department of Community Services,
307 Black Street, 1st Floor, P.O. Box 2703, C-6, Whitehorse, Yukon Y1A 2C6, Telephone: (867) 667-5466, Email: securities@gov.yk.ca.

 

		11.	We hereby represent, warrant, covenant and certify that we are, or any party on whose behalf we are acting
is, an “accredited investor” as defined in NI 45-106 or section 73.3(1) of the Securities Act (Ontario) by virtue of
satisfying the indicated criterion below:

 

Please check the category that applies:

 

	☐	(a)	
    Except for a Purchaser resident in Ontario, a
    Canadian financial institution, or a Schedule III bank.

     

    For a purchaser resident in Ontario, a financial
    institution described in paragraph 1, 2 or 3 of subsection 73.1(1) of the Securities Act (Ontario).

	☐	(b)	the Business Development Bank of Canada incorporated under the Business Development Bank of Canada Act (Canada),
	☐	(c)	a subsidiary of any person or company referred to in paragraphs (a) or (b) if the person or company owns all of the voting securities of the subsidiary, except the voting securities required by law to be owned by directors of that subsidiary,
	☐	(d)	a person or company registered under the securities legislation of a province or territory of Canada as an adviser or dealer, except as otherwise prescribed by the regulations,
	 	(e)	[omitted]
	 	(e.1)	[omitted]
	☐	(f)	the Government of Canada, the government of a province or territory of Canada, or any Crown corporation, agency or wholly owned entity of the Government of Canada or of the government of a province or territory of Canada,
	☐	(g)	a municipality, public board or commission in Canada and a metropolitan community, school board, the Comité de gestion de la taxe scolaire de l’île de Montréal or an intermunicipal management board in Québec,
	☐	(h)	any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any agency of that government,
	☐	(i)	a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a pension commission or similar regulatory authority of a province or territory of Canada,
	 	(j)	an individual who, either alone or with a spouse, beneficially owns financial assets having an aggregate realizable value that, before taxes but net of any related liabilities, exceeds CAD$1,000,000.  [Please complete Appendix “A”.]

 

    Schedule B - 4

    

    

 

	☐	(j.1)	an individual who beneficially owns financial assets having an aggregate realizable value that before taxes, but net of any related liabilities, exceeds CAD$5,000,000,
	 	(k)	an individual whose net income before taxes exceeded CAD$200,000 in each of the two most recent calendar years or whose net income before taxes combined with that of a spouse exceeded CAD$300,000 in each of the two most recent calendar years and who, in either case, reasonably expects to exceed that net income level in the current calendar year.  [Please complete Appendix “A”.]
	 	(l)	an individual who, alone or with a spouse, has net assets of at least CAD$5,000,000.  [Please complete Appendix “A”.]
	☐	(m)	a person, other than an individual or investment fund, that has net assets of at least $5,000,000 as shown on its most recently prepared financial statements,
	☐	(n)	an investment fund that distributes or has distributed its securities only to
	 	 	(i) a person that is or was an accredited investor at the time of the distribution,
	 	 	(ii) a person that acquires or acquired securities in the circumstances referred to in sections 2.10 of NI 45-106 [Minimum amount investment], or 2.19 of NI 45-106 [Additional investment in investment funds], or
	 	 	(iii) a person described in paragraph (i) or (ii) that acquires or acquired securities under section 2.18 of NI 45-106 [Investment fund reinvestment],
	☐	(o)	an investment fund that distributes or has distributed securities under a prospectus in a jurisdiction of Canada for which the regulator or, in Québec, the securities regulatory authority, has issued a receipt,
	☐	(p)	a trust company or trust corporation registered or authorized to carry on business under the Trust and Loan Companies Act (Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on behalf of a fully managed account managed by the trust company or trust corporation, as the case may be,
	☐	(q)	a person acting on behalf of a fully managed account1 managed by that person, if that person is registered or authorized to carry on business as an adviser or the equivalent under the securities legislation of a jurisdiction of Canada or a foreign jurisdiction,
	☐	(r)	a registered charity under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser or an adviser registered under the securities legislation of the jurisdiction of the registered charity to give advice on the securities being traded,
	☐	(s)	an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) through (d) or paragraph (i) in form and function,
	☐	(t)	a person in respect of which all of the owners of interests, direct, indirect or beneficial, except the voting securities required by law to be owned by directors, are persons that are accredited investors,
	☐	(u)	an investment fund that is advised by a person registered as an adviser or a person that is exempt from registration as an adviser,
	☐	(v)	a person that is recognized or designated by the securities regulatory authority as an accredited investor,
	☐	(w)	a trust established by an accredited investor for the benefit of the accredited investor’s family members of which a majority of the trustees are accredited investors and all of the beneficiaries are the accredited investor’s spouse, a former spouse of the accredited investor or a parent, grandparent, brother, sister, child or grandchild of that accredited investor, of that accredited investor’s spouse or of that accredited investor’s former spouse.

 

 

 1 A “fully managed account” means an account of a client for which a person makes the investment decisions if that person has full discretion to trade in securities for the account without requiring the client’s express consent to a transaction.

 

    Schedule B - 5

    

    

 

APPENDIX “A”

 

RISK ACKNOWLEDGEMENT FORM

 

Form 45-106F9

Risk Acknowledgement Form for Accredited Investors

 

	
     

    WARNING!

    This investment is risky. Don’t invest unless you can afford to lose all the money you pay

    for this investment.

	SECTION 1 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER
	1.  About your investment
	Class A Common Stock	Issuer:  DPCM Capital Inc. 
	Purchased from:  DPCM Capital Inc.
	SECTIONS 2 TO 4 TO BE COMPLETED BY THE PURCHASER
	2.  Risk acknowledgement
	This investment is risky. Initial that you understand that:	Your

initials
	Risk of loss – You could lose your entire investment of $___________. [Instruction: Insert the total dollar amount of the investment.]	 
	Liquidity risk – You may not be able to sell your investment quickly – or at all.	 
	Lack of information – You may receive little or no information about your investment. 	 
	Lack of advice -- You will not receive advice from the salesperson about whether this investment is suitable for you unless the salesperson is registered.  The salesperson is the person who meets with, or provides information to, you about making this investment.  To check whether the salesperson is registered, go to www.aretheyregistered.ca.	 
	 	 	 

 

    A - 1

    

    

 

	3.  Accredited investor status
	You must meet at least one of the following criteria to be able to make this investment. Initial all of the statements that apply to you.  The person identified in section 6 is responsible for ensuring that you meet the definition of accredited investor.  That person, or the salesperson identified in section 5, can help you if you have questions about whether you meet these criteria.	Your

initials
	Your net income before taxes was more than $200,000 in each of the 2 most recent calendar years, and you expect it to be more than $200,000 in the current calendar year.  (You can find your net income before taxes on your personal income tax return.)	 
	Your net income before taxes combined with your spouse’s was more than $300,000 in each of the 2 most recent calendar years, and you expect your combined net income before taxes to be more than $300,000 in the current calendar year.	 
	Either alone or with your spouse, you own more than $1 million in cash and securities, after subtracting any debt related to the cash and securities.	 
	Either alone or with your spouse, you have net assets worth more than $5 million.  (Your net assets are your total assets (including real estate) minus your total debt.)	 
	4.  Your name and signature
	By signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified in this form. 
	First and last name (please print):
	Signature:	Date:
	SECTION 5 TO BE COMPLETED BY THE SALESPERSON
	5.  Salesperson information
	[Instruction: The salesperson is the person who meets with, or provides information to, the purchaser with respect to making this investment.  That could include a representative of the issuer or selling security holder, a registrant or a person who is exempt from the registration requirement.]
	First and last name of contact person [please print]:
	Telephone:	Email:
	Name of firm (if registered):
	 	 	 	 

 

    A - 2

    

    

 

	
    

    SECTION 6 TO BE COMPLETED BY THE ISSUER

	6.  For more information about this investment
	DPCM Capital Inc.
	382 NE 191 Street, #24148
	Contact person: ●
	Telephone number: ●
	[Email]  
	[Website]
	 
	For
    more information about prospectus exemptions, contact your local securities regulator. You can find contact information at www.securities-administrators.ca.
	
    
 

    Form Instructions:

    1. This
    form does not mandate the use of a specific font size or style but the font must be legible.

    2. The
    information in sections 1, 5 and 6 must be completed before the purchaser completes and signs the form.

    3. The purchaser
must sign this form. Each of the purchaser and the issuer must receive a copy of this form signed by the purchaser. The issuer is required
to keep a copy of this form for 8 years after the distribution. 

 

 

A - 3EX-4.2

 Exhibit 4.2 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of March, 2020 by and among Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred
to in this Agreement as an “Investor”, and any Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof. 

RECITALS 

WHEREAS, the Company and certain of the Investors are parties to that certain Series C Preferred Stock Purchase Agreement of even date
herewith (the “Purchase Agreement”); 
 WHEREAS, certain of the existing Investors are parties to that certain
Amended and Restated Investors’ Rights Agreement dated May 23, 2019 by and among the Company and the parties thereto (the “Prior Agreement”), and in connection with the Purchase Agreement, the Company and such Investors
desire to amend and restate the Prior Agreement in its entirety as set forth herein; and 
 WHEREAS, in order to induce the Company
to enter into the Purchase Agreement and to induce certain of the Investors to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to
cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in
this Agreement. 
 NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered investment company now or hereafter
existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management company or investment adviser with, such Person. 

1.2 “ARCH” means ARCH Venture Partners IX, L.P. and ARCH Partners IX Overage, L.P. and their Affiliates. 

1.3 “AstraZeneca” means AstraZeneca AB and its Affiliates. 

1.4 “Board of Directors” means the board of directors of the Company. 

1.5 “Certificate of Incorporation” means the Company’s Amended and Restated Certificate of Incorporation, as amended
and/or restated from time to time. 
 1.6 “Common Stock” means shares of the Company’s common stock, par value $0.0001
per share. 
  

 1.7 “Competitor” means a Person engaged, directly or indirectly (including
through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in any line of business that the Board of Directors determines in good faith is substantially
competitive with the principal business of the Company as presently conducted and proposed to be conducted; but shall not include any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than
twenty percent (20%) of the outstanding equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of any Competitor. In no event shall ARCH, Gemini or Milky Way be considered
a Competitor. 
 1.8 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may
become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged
untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged
omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or
Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.9 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.10 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.11 “Excluded
Registration” means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration
relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities;
or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.12 “Form S-1” means such form under the Securities Act as in effect on the
date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.13 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of
substantial information by reference to other documents filed by the Company with the SEC. 
 1.14 “GAAP” means generally
accepted accounting principles in the United States as in effect from time to time. 
 1.15 “Gemini” means Gemini
Investments, L.P. and its Affiliates. 
 1.16 “GSK” means Glaxo Group Limited and its Affiliates. 

  
 2 

 1.17 “Holder” means any holder of Registrable Securities who is a party to
this Agreement. 
 1.18 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law,
or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.19 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 1.20 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 1.21 “Key Employee” means any executive-level employee (including, division director and vice president-level positions)
as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

1.22 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least
7,736,917 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof); provided, however, that (i) GSK shall be considered a
“Major Investor” for purposes of Section 4 only for so long as GSK, together with GSK’s Affiliates, holds at least 4,539,867 shares of Common Stock issuable or issued upon conversion of Series AA Preferred
Stock (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof) and the Board of Directors has not reasonably determined that GSK is a Competitor, and GSK shall not
be considered a “Major Investor” for any other purpose under this Agreement; and (ii) AstraZeneca shall be considered a “Major Investor” for so long as AstraZeneca, together with AstraZeneca’s Affiliates, holds at least
1,227,102 shares of Common Stock issuable or issued upon conversion of Series C Preferred Stock (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.23 “Milky Way” means Milky Way Investments Group Limited and its Affiliates. 

1.24 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.25 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.26 “Preferred Stock” means shares of the Company’s Series A Preferred Stock, Series B Preferred Stock, Series AA
Preferred Stock and Series C Preferred Stock. 
 1.27 “Registrable Securities” means (i) (A) except for the purposes
of the expression “majority of the Registrable Securities” as used herein, the Common Stock issuable or issued upon conversion of the Preferred Stock; and (B) for the purposes of the expression “majority of the Registrable
Securities” (including “majority of the Registrable Securities then outstanding”) as used herein, 

  
 3 

 
the Common Stock issuable or issued upon conversion of the Senior Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly)
upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant,
right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding (a) in all cases, any Registrable
Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1 and (b) for purposes of Section 2 any shares for which registration
rights have terminated pursuant to Subsection 2.13 of this Agreement. 
 1.28 “Registrable Securities then
outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then
exercisable and/or convertible securities that are Registrable Securities. 
 1.29 “Restricted Securities” means the
securities of the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof. 
 1.30
“SEC” means the Securities and Exchange Commission. 
 1.31 “SEC Rule 144” means Rule 144 promulgated by
the SEC under the Securities Act. 
 1.32 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

 1.33 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 1.34 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes
applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6.

 1.35 “Senior Preferred Stock” means shares of the Company’s Series A Preferred Stock, Series B Preferred
Stock and Series C Preferred Stock. 
 1.36 “Series A Director” means any director of the Company that the
holders of record of the Series A Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation. 

1.37 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0001 per share.

 1.38 “Series AA Preferred Stock” means shares of the Company’s Series AA Preferred Stock, par value $0.0001 per
share. 
 1.39 “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0001
per share. 

  
 4 

 1.40 “Series C Preferred Stock” means shares of the Company’s Series
C Preferred Stock, par value $0.0001 per share. 
 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the date hereof
or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Investors holding not less than forty percent (40%) of the Registrable Securities, which
Investors must include Major Investors holding not less than forty percent (40%) of the Registrable Securities then held by all Major Investors, that the Company file a Form S-1 registration statement with
respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $35 million, then the Company shall (x) within ten (10) days after the date such
request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by
the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable
Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the
limitations of Subsections 2.1(c) and 2.3. 
 (b) Form S-3 Demand. If at
any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Major Investors holding not less than twenty percent (20%) of the Registrable Securities then held by
all Major Investors that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling
Expenses, of at least $20 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and
in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities
requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of
Subsections 2.1(c) and 2.3. 
 (c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders
requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the
Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially
interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving
as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with
respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however, that the Company may
not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such one hundred twenty
(120) day period other than pursuant to a registration relating 

  
 5 

 
to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; a registration on any form that does
not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or a registration in which the only Common Stock being registered is Common Stock
issuable upon conversion of debt securities that are also being registered. 
 (d) The Company shall not be obligated to effect, or to take
any action to effect, any registration pursuant to Subsection 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one
hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become
effective; (ii) after the Company has effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on
Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection
2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated
registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to
Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time
as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand
registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d); provided, that if such withdrawal is
during a period the Company has deferred taking action pursuant to Subsection 2.1(c), then the Initiating Holders may withdraw their request for registration and such registration will not be counted as “effected” for
purposes of this Subsection 2.1(d). 
 2.2 Company Registration. If the Company proposes to register (including, for
this purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the
provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such
withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 
 2.3 Underwriting
Requirements. 
 (a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The
underwriter(s) will be selected by the Board of Directors and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such
registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s 

  
 6 

 
Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as
provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the underwriter(s)
advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be
underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the
Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection
2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and
then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be
included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to
include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine
that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as
practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall (i) the number of
Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the
offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination
described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability
company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any
trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable
Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 
 2.4 Obligations of the
Company. Whenever required under this Section 2.4 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred

  
 7 

 
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that such one hundred twenty
(120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration;

 (b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection
with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available for
inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

  
 8 

 In addition, the Company shall ensure that, at all times after any registration statement
covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 
 2.5 Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses
of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling
Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one
registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition,
business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such
expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2
shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 
 2.7
Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 2. 
 2.8 Indemnification. If any Registrable Securities
are included in a registration statement under this Section 2: 
 (a) To the extent permitted by law, the Company
will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for
each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or
other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however,
that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not
be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any
such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 

  
 9 

 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will
indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and
accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each
case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages
may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such
settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution
under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action
(including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give
the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which
notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without
conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be
inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate
losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in
connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to 

  
 10 

 
information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount
in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this
Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such
Holder), except in the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing, to the extent that the
provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall
control. 
 (f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering,
the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive
the termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of
SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the
Company shall: 
 (a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule
144, at all times after the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially
reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and

 (c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate,
a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any
time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form
S-3 (at any time after the Company so qualifies to use such form). 
 2.10 Limitations on
Subsequent Registration Rights. From and after the date hereof, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or
prospective holder of any securities of the Company that would (i) allow such holder or prospective holder to include such 

  
 11 

 
securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the
inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder
or prospective holder; provided that this limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with Subsection 6.9. 

2.11 “Market Stand-off” Agreement. Each Holder hereby agrees
that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company for its own behalf of shares of its Common Stock or any
other equity securities under the Securities Act on a registration statement on Form S-1 or Form S-3, and ending on the date specified by the Company and the managing underwriter (such period not to
exceed one hundred eighty (180) days in the case of the IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports,
and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract
to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement or (ii) enter into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or
otherwise. The foregoing provisions of this Subsection 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any
trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that
any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar
agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection
with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party
hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further
effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company stockholders that are subject to such agreements, based on the number
of shares subject to such agreements. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 

  
 12 

 (b) Each certificate, instrument, or book entry representing (i) the Preferred Stock,
(ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event,
shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall
give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the
effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or
transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the
terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such
Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or
book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except
that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the
Securities Act. 

  
 13 

 2.13 Termination of Registration Rights. The right of any Holder to request
registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation; 

(b) such time after consummation of the IPO as Rule 144 or another similar exemption under the Securities Act is available for the sale of
all of such Holder’s shares without limitation during a three-month period without registration; or 
 (c) the fifth anniversary of
the IPO. 
 3. Information and Inspection Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors has
not reasonably determined that such Major Investor is a Competitor: 
 (a) as soon as practicable, but in any event within one hundred
twenty (120) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of
and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in Subsection 3.1(d)) for such year, with an explanation of any material differences between such amounts and a
schedule as to the sources and applications of funds for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of
nationally or regionally recognized standing selected by the Company; 
 (b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company and within ninety (90) days after the end of the last quarter of each fiscal year of the
Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject
to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the
Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or
exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for
issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company; 

(d) as soon as practicable, but in any event within sixty (60) days after the end of each fiscal year, a budget and business plan for the
next fiscal year (collectively, the “Budget”), approved by the Board of Directors (including at least one Series A Director), and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow
for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; and 

  
 14 

 (e) such other information relating to the financial condition, business, prospects, or
corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide information (i) that
the Company reasonably determines in good faith to be a trade secret or similarly confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which would
adversely affect the attorney-client privilege between the Company and its counsel. 
 If, for any period, the Company has any subsidiary
whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all
such consolidated subsidiaries. 
 Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease
providing the information set forth in this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably
concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the
Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 
 3.2
Inspection. The Company shall permit each Major Investor (provided that the Board of Directors has not reasonably determined that such Major Investor is a Competitor), at such Major Investor’s expense, to visit and inspect the
Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor;
provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or similarly confidential
information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Observer Rights. As long as ARCH owns not less than twenty percent (20%) of the shares of the Series A Preferred Stock purchased by
it under that certain Series A Preferred Stock Purchase Agreement, dated September 20, 2018 and amended from time to time (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of
ARCH to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same
time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and
provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect
the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest. 
 3.4
Termination of Information and Observer Rights. The covenants set forth in Subsection 3.1, Subsection 3.2 and Subsection 3.3 shall terminate and be of no further force or effect
(i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed
Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

  
 15 

 3.5 Confidentiality. Each Investor agrees that such Investor will keep confidential
and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s
intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has
been independently developed or conceived by such Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of
confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to
obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this
Subsection 3.5; (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is
confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, regulation, rule, court order or subpoena, provided that such Investor promptly notifies the Company
of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 
 4. Rights to Future Stock
Issuances. 
 4.1 Rights of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable
securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it
among itself and its Affiliates in such proportions as it deems appropriate; provided that any Investor that the Board of Directors has reasonably determined to be a Competitor shall not be entitled to any rights as a Major Investor
under this Subsection 4.1. 
 (a) The Company shall give notice (the “Offer Notice”) to each Major Investor, stating
(i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company then outstanding (assuming
full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects to
purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such
notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were

  
 16 

 
entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon
conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or
exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection
4.1(b) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 

(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection
4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or
Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement
is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this
Subsection 4.1. 
 (d) The right of first offer in this Subsection 4.1 shall not be applicable to
(i) Exempted Securities (as defined in the Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of shares of Series C Preferred Stock pursuant to the Purchase Agreement. 

4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or effect
(i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed
Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 
 5. Additional
Covenants. 
 5.1 Insurance. The Company shall use commercially reasonable efforts to maintain Directors and Officers liability
insurance obtained from financially sound and reputable insurers in an amount and on terms and conditions satisfactory to the Board of Directors, including both Series A Directors, until such time as the Board of Directors determines that such
insurance should be discontinued. 
 5.2 Employee Agreement. The Company will cause (i) each Person now or hereafter employed by
it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and
(ii) each Key Employee to enter into a one (1) year nonsolicitation agreement, in a form reasonably acceptable to the Board of Directors, including at least one Series A Director. In addition, the Company shall not amend, modify,
terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the unanimous consent of the Series A Directors. 

  
 17 

 5.3 Employee Stock. Unless otherwise approved by the Board of Directors, including
at least one Series A Director, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute
restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued
employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off
provision substantially similar to that in Subsection 2.11. Without the prior approval by the Board of Directors, including at least one Series A Director, the Company shall not amend, modify, terminate, waive or otherwise alter, in whole or
in part, any stock purchase, stock restriction or option agreement with any existing employee or service provider if such amendment would cause it to be inconsistent with this Subsection 5.3. In addition, unless otherwise approved by the
Board of Directors, including at least one Series A Director, the Company shall retain (and not waive) a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested
shares at cost upon termination of employment of a holder of restricted stock. 
 5.4 Qualified Small Business Stock. The Company
shall use commercially reasonable efforts to cause the shares of Series A Preferred Stock originally issued on September 20, 2018, as well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the
Internal Revenue Code (the “Code”), to constitute “qualified small business stock” as defined in Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board
of Directors of the Company determines, in its good-faith business judgment, that such qualification is inconsistent with the best interests of the Company. The Company shall submit to its stockholders (including the Investors) and to the Internal
Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In addition, within twenty (20) business days after any Investor’s written request therefor, the
Company shall, at its option, either (i) deliver to such Investor a written statement indicating whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined in
Section 1202(c) of the Code or (ii) deliver to such Investor such factual information in the Company’s possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s
interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code. 
 5.5
Matters Requiring Investor Director Approval. So long as the holders of Series A Preferred Stock are entitled to elect a Series A Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval
of the Board of Directors, which approval must include the affirmative vote of at least one of the Series A Directors: 
 (a) make, or
permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

(b) make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the
Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors; 

(c) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade
accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (d) make any investment inconsistent with any
investment policy approved by the Board of Directors; 

  
 18 

 (e) incur any aggregate indebtedness in excess of $250,000 that is not already included in
a budget approved by the Board of Directors, other than trade credit incurred in the ordinary course of business; 
 (f) otherwise enter
into or be a party to any transaction with any director, officer, or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person,
except for transactions contemplated by the Purchase Agreement; 
 (g) hire, terminate, or change the compensation of the executive
officers, including approving any option grants or stock awards to executive officers; 
 (h) change the principal business of the Company,
enter new lines of business, or exit the current line of business; 
 (i) sell, assign, license, pledge, or encumber material technology or
intellectual property, other than licenses granted in the ordinary course of business; or 
 (j) enter into any corporate strategic
relationship involving the payment, contribution, or assignment by the Company or to the Company of money or assets greater than $10,000,000. 

5.6 Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall
meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel
expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. The Company shall cause to be established, as soon as practicable after such request, and will maintain, an audit
and compensation committee, each of which shall consist solely of non-management directors. Each Series A Director shall be entitled in such person’s discretion to be a member of any committee of the
Board of Directors. 
 5.7 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or
merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the
obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, the Certificate of Incorporation,
or elsewhere, as the case may be. 
 5.8 Expenses of Counsel. In the event of a transaction which is a Sale of the Company (as
defined in the Voting Agreement of even date herewith among the Investors, the Company and the other parties named therein), the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the Major Investors (“Investor
Counsel”), in their capacities as stockholders, shall be borne and paid by the Company. At the outset of considering a transaction which, if consummated would constitute a Sale of the Company, the Company shall obtain the ability to share
with the Investor Counsel (and such counsel’s clients) and shall share the confidential information (including, without limitation, the initial and all subsequent drafts of memoranda of understanding, letters of intent and other transaction
documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing any of the transactions which, individually or when aggregated with others would constitute the Sale of the
Company. The Company shall be obligated to share (and cause the 

  
 19 

 
Company’s counsel and investment bankers to share) such materials when distributed to the Company’s executives and/or any one or more of the other parties to such transaction(s). In the
event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter into a joint defense agreement or other arrangement to enhance the ability of the parties to protect their communications and other reviewed materials under the
attorney client privilege, the Company shall, and shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form and substance reasonably acceptable to Investor Counsel. In the event that one or more
of the other party or parties to such transactions require the clients of Investor Counsel to enter into a confidentiality agreement and/or joint defense agreement in order to receive such information, then the Company shall share whatever
information can be shared without entry into such agreement and shall, at the same time, in good faith work expeditiously to enable Investor Counsel and its clients to negotiate and enter into the appropriate agreement(s) without undue burden to the
clients of Investor Counsel. 
 5.9 Indemnification Matters. The Company hereby acknowledges that one (1) or more of the
directors nominated to serve on the Board of Directors by the Investors (each an “Investor Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and
certain of their Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Investor Director are primary and any
obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it shall be required to advance the full amount of expenses
incurred by such Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent legally permitted and as required by
the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights such Investor Director may have against the Investor Indemnitors, and,
(c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further
agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has sought indemnification from the Company shall affect the foregoing and the
Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against the Company. The Investor Directors and the Investor
Indemnitors are intended third-party beneficiaries of this Subsection 5.9 and shall have the right, power and authority to enforce the provisions of this Subsection 5.9 as though
they were a party to this Agreement. 
 5.10 Right to Conduct Activities. The Company hereby agrees and acknowledges that ARCH
(together with its Affiliates), Gemini (together with its Affiliates), Milky Way (together with its Affiliates), WuXi PharmaTech Healthcare Fund I L.P. (“WuXi”) (together with its Affiliates) and Foresite Capital Fund IV, L.P.
(“Foresite”) (together with its Affiliates) are each professional investment organizations, and that each of GSK (together with its Affiliates) and AstraZeneca (together with its Affiliates) engages in “corporate venture”
and other investment activities, and as such each of ARCH (and its Affiliates), Gemini (and its Affiliates), Milky Way (and its Affiliates), WuXi (and its Affiliates), Foresite (and its Affiliates), GSK (and its Affiliates) and AstraZeneca (and its
Affiliates) review the business plans and related proprietary information of many enterprises, some of which may compete directly or indirectly with the Company’s business (as currently conducted or as currently propose to be conducted). The
Company hereby agrees that, to the extent permitted under applicable law, ARCH (and its Affiliates), Gemini (and its Affiliates), Milky Way (and its Affiliates), WuXi (and its Affiliates), Foresite (and its Affiliates), GSK (and its Affiliates) and
AstraZeneca (and its Affiliates) shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by ARCH (or its Affiliates), 

  
 20 

 
Gemini (or its Affiliates), Milky Way (or its Affiliates), WuXi (or its Affiliates), Foresite (or its Affiliates), GSK (or its Affiliates) or AstraZeneca (or its Affiliates) in any entity
competitive with the Company, or (ii) actions taken by any partner, officer, employee or other representative of ARCH (or its Affiliates), Gemini (or its Affiliates), Milky Way (or its Affiliates), WuXi (or its Affiliates), Foresite (or its
Affiliates), GSK (or its Affiliates) or AstraZeneca (or its Affiliates) to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not
such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential information
obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

5.11 Termination of Covenants. The covenants set forth in this Section 5, except for Subsections
5.7, 5.9 and 5.10 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

5.12 Use of Investor Names. Neither the Company nor any Investor shall use the name of any other Investor in any press release,
published notice or other publication relating to any Investor’s investment in the Company without the prior written consent of such Investor. For the avoidance of doubt, the Company and the Investors may advise their respective tax, legal or
other professional advisors, other investors and prospective investors of the fact of the investment by the Investors in the Company, provided that such persons are obligated to keep such information confidential, and may make any other disclosure
regarding the Investors’ investment in the Company required by law or legal process provided that the Company or the Investor, as applicable provides each affected Investor reasonable advance notice of such disclosure. 

6. Miscellaneous. 
 6.1
Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a
Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds (a) at least 1,000,000 shares of Registrable
Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations) or (b) all of the shares of Registrable Securities held by the transferor prior to such transfer; provided,
however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being
transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of
determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a
trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify
individually for assignment of rights shall, as a condition to the applicable transfer, establish a single attorney-in-fact for the purpose of exercising any rights,
receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly
provided herein. 

  
 21 

 6.2 Governing Law. This Agreement shall be governed by the internal law of the State
of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. 

(a) All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business
hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit
with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their
addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently
modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy (which shall not constitute notice) shall also be sent to Cooley LLP, 101 California Street, 5th Floor, San Francisco, CA 94111, Attn: David Peinsipp. 
 (b) Consent to Electronic
Notice. Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant to
Section 232 of the DGCL (or any successor thereto) at the electronic mail address or the facsimile number as on the books of the Company. Each Investor agrees to promptly notify the Company of any change in such Investor’s electronic mail
address, and that failure to do so shall not affect the foregoing. 
 6.6 Amendments and Waivers. Any term of this Agreement may be
amended, modified or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of
a majority of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after
notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s
own behalf, without the consent of any other party. Notwithstanding the foregoing, (a) this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor or series of
Preferred Stock without the written 

  
 22 

 
consent of such Investor or holders of a majority of the outstanding shares of such series of Preferred Stock, unless such amendment, modification, termination, or waiver applies to all Investors
or each series of Preferred Stock, as the case may be, in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in
the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction), (b) Subsections 3.1 and 3.2,
Section 4 and any other section of this Agreement applicable to the Major Investors (including this clause (b) of this Subsection 6.6) may not be amended, modified, terminated or waived without the
written consent of the holders of at least a majority of the Registrable Securities then outstanding and held by the Major Investors, (c) Subsection 3.3 may not be amended, modified, terminated or waived without the written
consent of ARCH, and (d) notwithstanding any waiver of any of the provisions of Section 4 with respect to a particular offering of New Securities, in the event any Major Investor that elected to waive
Section 4 with respect to such offering (each, a “Waiving Investor”) actually purchases any such New Securities in such offering, then each other Major Investor shall be permitted to participate in such
offering on a pro rata basis (based on the pro rata level of participation of the Waiving Investor purchasing the largest portion of such Waiving Investor’s pro rata share of the New Securities), in accordance with the other provisions
(including notice and election periods) set forth in Section 4. Notwithstanding the foregoing, Schedule A hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in
compliance with the terms of this Agreement without the consent of the other parties; and Schedule A hereto may also be amended by the Company after the date hereof without the consent of the other parties to add information regarding any
additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. The Company shall give prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not
consent in writing to such amendment, modification, termination, or waiver. Any amendment, modification, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of
whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term,
condition, or provision. 
 6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason
held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and
construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Stock. All
shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves
in any manner they deem appropriate. Shares of Registrable Securities held by each of Milky Way, Gemini and their respective Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement
and the bylaws of the Company (including Major Investor status) and such persons may apportion and assign such rights as among themselves in any manner they deem appropriate. 

6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the
Company’s Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart
signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as
such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

  
 23 

 6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto)
constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly
canceled. 
 6.11 Dispute Resolution. Any unresolved controversy or claim arising out of or relating to this Agreement, except as
(i) otherwise provided in this Agreement, or (ii) any such controversies or claims arising out of either party’s intellectual property rights for which a provisional remedy or equitable relief is sought, shall be submitted to
arbitration by one arbitrator mutually agreed upon by the parties, and if no agreement can be reached within thirty (30) days after names of potential arbitrators have been proposed by the American Arbitration Association (the
“AAA”), then by one arbitrator having reasonable experience in corporate finance transactions of the type provided for in this Agreement and who is chosen by the AAA. The arbitration shall take place in Wilmington, Delaware, in
accordance with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding and may be entered in any court having jurisdiction thereof. There shall be limited discovery prior to the arbitration hearing as
follows: (a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party witnesses and (c) such other depositions as may be allowed
by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance with the Delaware Code of Civil Procedure, the arbitrator shall be required to provide in writing to the parties the basis for the award or order of such
arbitrator, and a court reporter shall record all hearings, with such record constituting the official transcript of such proceedings. 
 WAIVER OF JURY
TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS
WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT
CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO
HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

6.12 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or
to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law
or otherwise afforded to any party, shall be cumulative and not alternative. 

  
 24 

 6.13 Amendments of Prior Agreement. Effective and contingent upon execution of this
Agreement by (a) the Company and (b) the holders of a majority of the outstanding Registrable Securities (as defined in the Prior Agreement), the Prior Agreement is hereby amended and restated in its entirety to read as set forth in this
Agreement, and the Company and Investors hereby agree to be bound by the provisions hereof as the sole agreement of the parties with respect to the rights set forth herein. 

[Remainder of Page Intentionally Left Blank] 

  
 25 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	COMPANY:
	
	LYELL IMMUNOPHARMA, INC.
		
	By:	 	 /s/ Richard D. Klausner

			
	Name: Richard D. Klausner
	Title: Chief Executive Officer

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	MILKY WAY INVESTMENTS GROUP LIMITED
		
	By:	 	 /s/ Despoina Zinonos

			
	Print Name: Despoina Zinonos
	Title: President

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	WUXI PHARMATECH HEALTHCARE FUND I L.P.
		
	By:	 	 /s/ Edward Hu

	Name: Edward Hu
	Title: Authorized Signatory

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	AstraZeneca AB
		
	By:	 	 /s/ Yvonne Bertlin

	Print Name: Yvonne Bertlin
	Title: CFO

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	GV 2019, L.P.
	By:	 	GV 2019 GP, L.P., its General Partner
	Its:	 	GV 2019 GP, L.L.C., its General Partner
		
	By:	 	 /s/ Daphne M. Chang

	Name: Daphne M. Chang
	Title: Authorized Signatory

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	SCC Growth V 2020-A, L.P.
		
	By:	 	 /s/ Ip Siu Wai Eva

	Name: Ip Siu Wai Eva
	Title: Authorized Signatory

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	FORESITE CAPITAL FUND IV, L.P.
		
	By:	 	Foresite Capital Management IV, LLC
	Its:	 	General Partner
		
	By:	 	 /s/ Dennis D. Ryan

	Name: Dennis D. Ryan
	Title: Chief Financial Officer

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	ARCH VENTURE FUND IX, L.P.
	By: ARCH Venture Partners IX, L.P.,
	its General Partner
	By: ARCH Venture Partners IX, LLC,
	its General Partner
		
	By:	 	 /s/ Mark McDonnell

	Name: Mark McDonnell
	Title: Managing Director
	
	ARCH VENTURE FUND IX OVERAGE, L.P.
	 By: ARCH Venture Partners IX Overage, L.P.,

its General Partner

	By: ARCH Venture Partners IX, LLC,
	its General Partner
		
	By:	 	 /s/ Mark McDonnell

	Name: Mark McDonnell
	Title: Managing Director

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	HH LYL HOLDINGS LIMITED
		
	By:	 	 /s/ Colm John O’ Connell

	Print Name: Colm John O’ Connell
	Title: Authorized Signatory

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	MDC CAPITAL PARTNERS (VENTURES) LP
	acting by its general partner,
	MDC Capital Partners (Ventures) GP, LP
	itself acting by its general partner,
	MDC Capital Partners (Ventures) GP, LLC
		
	By:	 	 /s/ Howard Caro

	Name: Howard Caro
	Title: Authorized Signatory

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	Richard D. Klausner and Rachel D.
	Klausner, Trustees of the Klausner Family
	Revocable Trust of May 8, 2014
		
	By:	 	 /s/ Richard Klausner

	Print Name: Richard Klausner
		
	By:	 	 /s/ Rachel D. Klausner

	Print Name: Rachel D. Klausner

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	GEMINI INVESTMENTS, L.P.
		
	By:	 	Gemini GP Limited
	Its:	 	General Partner
		
	By:	 	 /s/ David Muir

	Name: David Muir
	Title: President

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	 INVESTOR:
  

THE NGM FAMILY TRUST 2006 IRREVOCABLE

TRUST

		
	By:	 	 /s/ Thomas Scott

	Print Name: Thomas Scott
	 Title:  Associate; J. P. Morgan Trust Company of Delaware as
Trustee

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	 INVESTOR:
  

THE LI CHILDREN’S 2006 IRREVOCABLE

TRUST

		
	By:	 	 /s/ Thomas Scott

	Print Name: Thomas Scott
	Title:	 	Associate; J. P. Morgan Trust Company
		 	of Delaware as Trustee

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	EMERSON COLLECTIVE INVESTMENTS,
	LLC
	
	 /s/ Steve McDermid

	Steve McDermid, Authorized Signatory

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	LYELL INVESTORS, LLC
		
	By:	 	 /s/ Richard Klausner

	Print Name: Richard Klausner
	Title:	 	CEO

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	PARKER INSTITUTE FOR CANCER
	IMMUNOTHERAPY
		
	By:	 	 /s/ Melinda Griffith

	Print Name: Melinda Griffith
	Title: VP. Strategic Alliances

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

					
	 INVESTOR:
  
	 	
	GLAXO GROUP LIMITED
		 	

 
					
		
	By:	 	 /s/ JOHN SADLER

					
	Print Name: JOHN SADLER

 
					
	Title:	 	  

 [SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	GE LI
		
	By:	 	 /s/ GE LI

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	 INVESTOR:
  

NING ZHAO

		
	 By:
	 	 /s/ NING ZHAO

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	CREEKSTONE INVESTMENT, LLC
		
	By:	 	 /s/ Paul Dauber

	Name: Paul Dauber
	Title: Manager
	
	Address:
	Attn: Paul Dauber, Manager
	PO Box 94314
	Seattle, WA 98124

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	EXPLORE INVESTMENTS LLC
		
	By:	 	 /s/ Paul Dauber

	Name: Paul Dauber
	Title: Manager
	
	Address:
	Attn: Paul Dauber, Manager
	PO Box 94314
	Seattle, WA 98124

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 SCHEDULE A 

INVESTORS 
 8VC Entrepreneurs Fund II,
L.P. 
 8VC Fund II, L.P. 
 Akira Matsuno

 Alexandria Venture Investments, LLC 

Altitude Life Science Ventures Fund III, L.P. 
 ARCH
Venture Fund IX, L.P. 
 ARCH Venture Fund IX Overage, L.P. 

 AstraZeneca AB 

Bryan White 
 Celgene Corporation 

Dechomai Foundation, Inc. 
 Emerson Collective
Investments, LLC 
 Explore Holdings LLC 
 First
Brilliance Limited 
 Foresite Capital Fund IV, L.P. 

 Gates Frontier, LLC 

Gemini Investments, L.P. 
 Glaxo Group Limited

 GV 2019, L.P. 
 Hans Bishop 

HH LYL Holdings Limited 
 Lyell Investors, LLC

 Lyon Street Investments, LLC 
 MDC Capital
Partners (Ventures) LP 

 Milky Way Investments Group Limited 

Parker Institute for Cancer Immunotherapy 
 Richard D
Klausner and Rachel D Klausner, 
 Trustees of the Klausner Family Revocable Trust of May 8, 2014 

SCC Growth V 2020-A, L.P. 

The Board of Trustees of the Leland Stanford Junior University (PVF) 

The Li Children’s 2006 Irrevocable Trust 
 The
NGM Family 2006 Irrevocable Trust 
 WuXi PharmaTech Healthcare Fund I L.P. 

 Ning Zhao 

Ge Li 
 Explore Investments LLC 

Creekstone Investment, LLC

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]